



CIN: L01400TG1986PLC062463

ARUNJYOTI BIO VENTURES LTD.

To,
BSE Limited
P.J.Towers, Dalal Street
Mumbai - 400001

Date: 05.12.2020

Dear Sir/Madam,

Sub: Annual Report for the Financial Year 2019-2020.

Ref: Scrip Code 530881

With reference to the subject cited, pursuant to Regulation 34 of SEBI (LODR) Regulations 2015, we are herewith enclosing the 34th Annual Report for the Financial Year 2019-20.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Faithfully,

For Arunjyoti Bio Ventures Limited




P. Praveen Kumar
Whole-Time Director
DIN: 02009879

**ARUNJYOTI BIO
VENTURES LIMITED**

**34th
ANNUAL REPORT
2019-20**

ARUNJYOTI BIO VENTURES LIMITED

CORPORATE INFORMATION:

BOARD OF DIRECTORS

1. Mr. Pabbathi Praveen Kumar - Whole-time Director cum CFO
(DIN: 02009879)
2. Mr. Raja Kumar Babulal - Whole-time Director (DIN: 07529064)
3. Mrs. Vanaja Kumari Dokiparthi - Independent Director (DIN: 07151205)
4. Mr. M Aditya Vardhan Reddy - Independent Director (DIN: 06897440)
5. Mr. Polsani Venkata Rama Rao - Independent Director (DIN: 00129932)
6. Mr. Chandra ShekarKondari - Independent Director (DIN: 08300152)

COMPANY SECRETARY :

Ms. Swati Jain
(Appointed on 19.09.2020)

REGISTERED OFFICE:

Plot No. 45, P & T Colony,
Karkhana, Secunderabad – 500009
E-mail id:cenport@gmail.com

STATUTORY AUDITORS:

M. M. Reddy & Co.,
Chartered Accountants,
Rajbhavan Road,
Somajiguda, Hyderabad

BANKERS:

ICICI Bank
Axis Bank

AUDIT COMMITTEE:

- 1) M Aditya Vardhan Reddy - Chairman
- 2) Vanaja KumariDokiparthi - Member
- 3) Raja Kumar Babulal - Member

NOMINATION & REMUNERATION COMMITTEE:

- 1) M Aditya Vardhan Reddy - Chairman
- 2) Polsani Venkata Rama Rao - Member
- 3) Vanaja KumariDokiparthi - Member

STAKEHOLDERS RELATIONSHIP COMMITTEE:

- 1) M Aditya Vardhan Reddy - Chairman
- 2) Polsani Venkata Rama Rao - Member
- 3) Raja Kumar Babulal - Member

ARUNJYOTI BIO VENTURES LIMITED

INDEPENDENT DIRECTORS:

- | | | |
|-----------------------------|---|----------|
| 1) Polsani Venkata Rama Rao | - | Chairman |
| 2) M Aditya Vardhan Reddy | - | Member |
| 3) Vanaja KumariDokiparthi | - | Member |
| 4) Chandra ShekarKondari | - | Member |

RISK MANAGEMENT COMMITTEE:

- | | | |
|-----------------------------|---|-------------|
| 1) Vanaja Kumari Dokiparthi | - | Chairperson |
| 2) M Aditya Vardhan Reddy | - | Member |
| 3) Raja Kumar Babulal | - | Member |

REGISTRAR & SHARE TRANSFER AGENTS:

Venture Capital and Corporate Investments
Private Limited
12-10-167, Bharat Nagar,
Hyderabad – 500 018

LISTED AT: BSE Limited

DEMAT ISIN NUMBER IN NSDL & CDSL: INE485K01014

WEBSITE: www.orbisagri.com

INVESTOR E-MAIL ID: cenport@gmail.com

CORPORATE IDENTITY NUMBER: L01400TG1986PLC062463

ARUNJYOTI BIO VENTURES LIMITED

NOTICE

NOTICE is hereby given that the 34th Annual General Meeting of the Members of Arunjyoti Bio Ventures Limited will be held on Monday, the 28th day of December, 2020 at 11:00 a.m. through Video Conferencing/ Other Audio Visual Means (OAVM) to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2020 and the Statement of Profit and Loss for the year ended as on that date along with Cash Flow Statement and notes appended thereto together with the Directors' Report and Auditors' Report thereon.
2. To appoint a Director in the place of Mr. P. Praveen Kumar (DIN: 02009879), who retires by rotation and being eligible, offers himself for re-appointment.
3. To appoint M/s. V Ravi&Co., as Statutory Auditors and to fix their remuneration and for the purpose to consider and if, thought fit, to pass with or without modification(s), the following Ordinary Resolution thereof:

“RESOLVED THAT pursuant to the provisions of sections 139, 142 and other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Audit and Auditors) Rules, 2014, (including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force), as may be applicable and pursuant to the recommendations of the Audit Committee, M/s. VRavi& Co., Chartered Accountants, (ICAI Firm Registration Number 006492S) be and are hereby appointed as the Statutory Auditors of the Company, to hold office for a term of 5 (five) years, from the conclusion of this Annual General Meeting until the conclusion of the Annual General Meeting of the Company to be held in the year 2025 on such remuneration plus service taxes, out-of-pocket expenses, etc. as may be mutually agreed upon by the Board of Directors and the Auditors”

“FURTHER RESOLVED THAT approval of the Company be and is hereby accorded to the Board of Directors of the Company (including any Committee thereof) to do all such acts, deeds, matters and things and to take all such steps as may be required in this connection including seeking all necessary approvals to give effect to this Resolution and to settle any questions, difficulties or doubts that may arise in this regard.

SPECIAL BUSINESS:

4. REAPPOINTMENT OF MR. VENKATRAMA RAO POLSANI AS INDEPENDENT DIRECTOR OF THE COMPANY

To consider and if thought fit, to pass with or without modification(s), the following resolution as Special Resolution:

“RESOLVED THAT pursuant to the provisions of Sections 149,150,152,160 and Schedule IV and other applicable provisions if any, of the Companies Act, 2013 including any statutory modification(s) or re-enactment thereof for the time being in force, Articles of Association of the Company, and pursuant to recommendation of the Nomination and Remuneration Committee and the Board of Directors, the approval of the Members of the Company be and is hereby accorded for re-appointment of Mr. Venkatrama Rao Polsani (DIN 00129932) whose current period of office expires on 29th May, 2021 and who has submitted a declaration confirming the criteria of Independence under Section 149(6) of the Companies Act, 2013 read with the Listing Regulations, as amended from time to time, and who is eligible for re-appointment for a second term under the provisions of the Companies Act, 2013, Rules made thereunder and Listing Regulations and whose term shall not be subject to retirement by rotation, to hold office for a term of 5 (five) consecutive years on the Board of the Company w.e.f. 30.05.2021 up to 29.05.2026.”

“RESOLVED FURTHER THAT the Board be and is hereby authorized to do all such acts, deeds, matters and things as may be considered necessary, appropriate and desirable to give effect to the resolution.”

5. REAPPOINTMENT OF MRS. VANAJA KUMARI DOKIPARTHI AS INDEPENDENT DIRECTOR OF THE COMPANY

To consider and if thought fit, to pass with or without modification(s), the following resolution as Special Resolution:

“RESOLVED THAT pursuant to the provisions of Sections 149,150,152,160 and Schedule IV and other applicable provisions if any, of the Companies Act, 2013 including any statutory modification(s) or re-enactment thereof for the time being in force, Articles of Association of the Company, and pursuant to recommendation of the Nomination and Remuneration Committee and the Board of Directors, the approval of the Members of the Company be and is hereby accorded for re-appointment of Mrs. Vanaja Kumari Dokiparthi (DIN 07151205) whose current period of office expires on 28th September, 2020 and who has submitted a declaration confirming the criteria of Independence under Section 149(6) of the Companies Act, 2013 read with the Listing Regulations, as

ARUNJYOTI BIO VENTURES LIMITED

amended from time to time, and who is eligible for re-appointment for a second term under the provisions of the Companies Act, 2013, Rules made thereunder and Listing Regulations and whose term shall not be subject to retirement by rotation, to hold office for a term of 5 (five) consecutive years on the Board of the Company w.e.f. 29.09.2020 up to 28.09.2025.”

"RESOLVED FURTHER THAT the Board be and is hereby authorized to do all such acts, deeds, matters and things as may be considered necessary, appropriate and desirable to give effect to the resolution.”

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Place: Secunderabad
Date: 04.12.2020**

**Sd/-
Rajakumar Babulal
Whole-time Director
(DIN: 07529064)**

ARUNJYOTI BIO VENTURES LIMITED

NOTES:

1. In view of the continuing Covid-19 pandemic, the Ministry of Corporate Affairs (“MCA”) has vide its circular dated May 5, 2020 read with circulars dated April 8, 2020 and April 13, 2020 (collectively referred to as “MCA Circulars”) permitted the holding of the Annual General Meeting (“AGM”) through VC / OAVM, without the physical presence of the Members at a common venue. In compliance with the provisions of the Companies Act, 2013 (“Act”), SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and MCA Circulars, the AGM of the Company is being held through VC / OAVM.
2. Pursuant to the provisions of the Act, a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice.
3. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting’s agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by CDSL.
4. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to all members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

ARUNJYOTI BIO VENTURES LIMITED

5. The attendance of the Members (members logins) attending the e-AGM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at www.orbisagri.com
7. The Notice can also be accessed from the websites of the Stock Exchange i.e. BSE Limited at www.bseindia.com. The AGM Notice is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility and e-voting system during the AGM) i.e. www.evotingindia.com.
8. Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 relating to the Special Business in the Notice is annexed hereto and forms part of this Notice.
9. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of Contracts or arrangements in which the directors are interested under Section 189 of the Companies Act, 2013, will be available for inspection at the AGM.
10. Shareholders holding shares in physical form may write to the company/company's R&T agents for any change in their address/bank mandate; shareholders holding shares in electronic form may inform the same to their depository participants immediately, where applicable.
11. The Register of Members and Share Transfer books of the company will remain closed from 22.12.2020 to 28.12.2020 (both days inclusive).
12. Corporate Members are requested to send to the Company's Registrar & Transfer Agent, a duly certified copy of the Board Resolution authorizing their representative to attend and vote at the Annual General Meeting.
13. The Securities and Exchange Board of India has mandated submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in demat form are, therefore, requested to submit PAN details to the Depository Participants with whom they have demat accounts. Members holding shares in physical form can submit their PAN details to the Company/ Registrar and Share Transfer Agents (M/s. Venture Capital and Corporate Investments Private Limited)
14. Members holding shares in the same name under different ledger folios are requested to apply for consolidation of such folios and send the

ARUNJYOTI BIO VENTURES LIMITED

relevant share certificates to M/s Venture Capital and Corporate Investments Private Limited) Share Transfer Agents of the Company for doing the needful.

15. Since securities of the Company are traded compulsorily in dematerialized form as per SEBI mandate, members holding shares in physical form are requested to get their shares dematerialized at the earliest.
16. Recent circular requires submission of Aadhar/PAN number by every participant in securities market. Members holding shares in demat form are, therefore, requested to submit Aadhar card/PAN details to the Depository Participants with whom they have demat accounts. Members holding shares in physical form can submit their Aadhar card/PAN details to the Company/ Registrar and Share Transfer Agents (Venture Capital and Corporate Investments Private Limited)
17. Members are requested to send their queries at least 10 days before the date of meeting so that information can be made available at the meeting.
18. In respect of shares held in physical mode, all shareholders are requested to intimate changes, if any, in their registered address immediately to the registrar and share transfer agent of the company and correspond with them directly regarding share transfer/transmission /transposition, Demat / Remat, change of address, issue of duplicate shares certificates, ECS and nomination facility.
19. In terms of Section 72 of the Companies Act, 2013, a member of the company may nominate a person on whom the shares held by him/her shall vest in the event of his/her death. Members desirous of availing this facility may submit nomination in prescribed Form-SH-13 to the company/RTA in case shares are held in physical form, and to their respective depository participant, if held in electronic form.
20. In compliance with the aforesaid MCA Circulars and SEBI Circular dated May 12, 2020, Notice of the AGM along with the Annual Report 2019-20 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/Depositories.
21. Members may also note that the Notice of the 34th Annual General Meeting and the Annual Report for 2019 - 20 will also be available on the Company's website www.orbisagri.com for their download. For any communication, the shareholders may also send requests to the Company's investor email id: cenport@gmail.com.

ARUNJYOTI BIO VENTURES LIMITED

22. Since the AGM will be held through VC / OAVM, the Route Map is not annexed in this Notice.

23. Instructions for e-voting and joining the AGM are as follows:

A. THE INTRUCTIONS FOR SHAREHOLDRES FOR REMOTE E-VOTING ARE AS UNDER:

- I. In compliance with provisions of Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended by the Companies (Management and Administration) Amendment Rules, 2015 and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the Members are provided with the facility to cast their vote electronically, through the e-voting services provided by Central Depository Services (India) Limited (CDSL) on all the resolutions set forth in this Notice. The instructions for e-voting are given herein below.
- II. The remote e-voting period commences on 25th day, December 2020 (9:00 a.m. IST) and ends on 27th day, December, 2020 (5:00 p.m. IST). During this period, Members holding shares either in physical form or in dematerialized form, as on 21st day, December, 2020 i.e. cut-off date, may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter. Those Members, who will be present in the AGM through VC / OAVM facility and have not cast their vote on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.
- III. The Members who have cast their vote by remote e-voting prior to the AGM may also attend/ participate in the AGM through VC / OAVM but shall not be entitled to cast their vote again. The members who have cast their vote by remote e-voting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again.
- IV. The voting rights of Members shall be in proportion to their shares in the paid-up equity share capital of the Company as on the cut-off date.
- V. The details of the process and manner for remote e-voting are explained herein below:
 - (i) The shareholders should log on to the e-voting website www.evotingindia.com.
 - (ii) Click on Shareholders tab.
 - (iii) Now Enter your User ID

ARUNJYOTI BIO VENTURES LIMITED

- a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Members holding shares in Physical Form should enter Folio Number registered with the Company.
- (iv) Next enter the Image Verification as displayed and Click on Login.
- (v) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier voting of any company, then your existing password is to be used.
- (vi) If you are a first time user follow the steps given below:

	For Members holding shares in Demat Form and Physical Form
PAN	<p>Enter your 10 digit alpha-numeric PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)</p> <ul style="list-style-type: none">• Members who have not updated their PAN with the Company/Depository Participant are requested to use the first two letters of their name and the 8 digits of the sequence number in the PAN field.• In case the sequence number is less than 8 digits enter the applicable number of 0's before the number after the first two characters of the name in CAPITAL letters. Eg. If your name is Ramesh Kumar with sequence number 1 then enter RA00000001 in the PAN field.
Date of Birth (DOB)	<p>Enter the Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login.</p> <ul style="list-style-type: none">• If the details are not recorded with the depository or company please enter the member id / folio number as mentioned in instruction (iii).

- (vii) After entering these details appropriately, click on “SUBMIT” tab.
- (viii) Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for

ARUNJYOTI BIO VENTURES LIMITED

voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

- (ix) For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (x) Click on the EVSN for the relevant <Arunjyoti Bio Ventures Limited> on which you choose to vote.
- (xi) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xii) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xiii) After selecting the resolution you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xiv) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xv) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xvi) If a demat account holder has forgotten the changed password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xvii) Shareholders can also cast their vote using CDSL’s mobile app m-Voting available for android based mobiles. The m-Voting app can be downloaded from Google Play Store. Apple and Windows phone users can download the app from the App Store and the Windows Phone Store respectively. Please follow the instructions as prompted by the mobile app while voting on your mobile.

B. INSTRUCTIONS FOR SHAREHOLDERS FOR E-VOTING DURING THE AGM ARE AS UNDER:

- (i) The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for Remote e-voting.

ARUNJYOTI BIO VENTURES LIMITED

- (ii) Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
- (iii) If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility , then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

C. NOTE FOR NON – INDIVIDUAL SHAREHOLDERS AND CUSTODIANS:

- (i) Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodian are required to log on to www.evotingindia.com and register themselves as Corporates.
- (ii) A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- (iii) After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- (iv) The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- (v) A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- (vi) Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer at the email address viveksurana24@gmail.com and to the Company at the email address viz; cenport@gmail.com, if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

ARUNJYOTI BIO VENTURES LIMITED

D. PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL ADDRESSES ARE NOT REGISTERED WITH THE DEPOSITORIES FOR OBTAINING LOGIN CREDENTIALS FOR E-VOTING:

- (i) For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to Company/RTA email id.
- (ii) For Demat shareholders -, please provide Demat account details (CDSL-16 digit beneficiary ID or NSDL-16 digit DPID + CLID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to Company/RTA email id.
- (iii) The company/RTA shall co-ordinate with CDSL and provide the login credentials to the above mentioned shareholders.

E. INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

- (i) Shareholder will be provided with a facility to attend the EGM/AGM through VC/OAVM through the CDSL e-Voting system. Shareholders may access the same at <https://www.evotingindia.com> under shareholders/members login by using the remote e-voting credentials. The link for VC/OAVM will be available in shareholder/members login where the EVSN of Company will be displayed.
- (ii) Shareholders are encouraged to join the Meeting through Laptops / iPads for better experience.
- (iii) Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
- (iv) Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least 5 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at company email id viz; cenport@gmail.com,. The shareholders who do

ARUNJYOTI BIO VENTURES LIMITED

not wish to speak during the AGM but have queries may send their queries in advance 5 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). These queries will be replied to by the company suitably by email.

- (v) Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
1. In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions (“FAQs”) and e-voting manual available at www.evotingindia.com, under help section or write an email to helpdesk.evoting@cdslindia.com or call 1800225533.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Shiva Prasad Venishetty, Senior Manager, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call 1800225533.

24. SEBI has decided that securities of the listed companies can be transferred only in dematerialized form which effective from 05.12.2018. In view of the above and to avail various benefits of dematerialization, members are advised to dematerialize shares held by them in physical form.
25. The voting rights of shareholders shall be in proportion to their shares of the paid up equity share capital of the Company as on the cut-off date (record date) of 21.12.2020.
26. M/s. Vivek Surana & Associates, Practicing Company Secretaries, has been appointed as the Scrutinizer to scrutinize the e-voting process in accordance with the law. The Scrutinizer shall, immediately after the conclusion of voting at the AGM, first count the votes cast during the AGM, thereafter unblock the votes cast through remote e-voting and make, not later than 48 hours of conclusion of the AGM, a consolidated Scrutinizer’s Report of the total votes cast in favour or against, if any, to the Chairman or a person authorised by him in writing, who shall countersign the same. The Results shall be declared on or after the AGM of the Company.
27. Relevant documents referred to in the accompanying Notice, as well as Annual Report are open for inspection at the Registered Office of the Company, during the office hours, on all working days between 10.00 A.M. to 5.00 P.M. up to the date of Annual General Meeting.

ARUNJYOTI BIO VENTURES LIMITED

28. The Results declared along with the Scrutinizer's Report shall be placed on the Company's website and on the website of CDSL within two(2) days of passing of the resolutions at the AGM of the Company and communicated to the BSE Limited.
29. The Ministry of Corporate Affairs (vide circular nos. 17/2011 and 18/2011 dated April 21 and April 29, 2011 respectively), has undertaken a 'Green Initiative in Corporate Governance' and allowed companies to share documents with its shareholders through an electronic mode. Members are requested to support this green initiative by registering/uploading their email addresses, in respect of shares held in dematerialized form with their respective Depository Participant and in respect of shares held in physical form with the Company's Registrar and Share Transfer Agents.

**For and on behalf of the Board
Arunjoti Bio Ventures Limited**

**Place: Secunderabad
Date: 04.12.2020**

**Sd/-
Rajakumar Babulal
Whole-time Director
(DIN: 07529064)**

ARUNJYOTI BIO VENTURES LIMITED

EXPLANATORY STATEMENT

Pursuant to Section 102(1) of the Companies Act, 2013

ITEM No. 3:

APPOINTMENT OF M/S V RAVI&Co., CHARTERED ACCOUNTANTS AS THE STATUTORY AUDITORS OF THE COMPANY:

Pursuant to the provisions of Section 139 of the Act read with applicable Rules framed thereunder, M/s. M.M. Reddy & Co, Chartered Accountants, the present Auditors of the Company shall complete their term as Auditors and in terms of their appointment made, they are holding office of the auditors up to the conclusion of the 34th AGM and hence, would retire at the conclusion of the forthcoming 34th AGM. M/s. M.M. Reddy & Co, Chartered Accountants will complete the term of appointment at the conclusion of the forthcoming Annual General Meeting. The Audit Committee and the Board of Directors have placed on record their appreciation for the professional services rendered by M/s. M.M Reddy & Co, Chartered Accountants during their association with the Company as its auditors.

For the purpose of appointment of new Auditors, the Audit Committee along with the Management, invited proposals from the firms of Chartered Accountants and had detailed discussion with representatives of those firms.

The Committee considered various parameters such as reputation of the firm, knowledge and experience of the partners, understanding of business, technical assessment of the Audit skills and the Audit fees and based on these detailed analysis, the Audit Committee recommended M/s. V Ravi & Co., Chartered Accountants (Firm Registration No. 006492S), Hyderabad as the Company's new Statutory Auditor. The Company will be paying the same fee (Rs.100,000 p.a. plus taxes as applicable) to the new auditors that it was paying to the retiring auditors.

M/s V RAVI AND Co., was established as a firm with the Institute of Chartered Accountants of India with Office at Warangal by Mr CA. V RAVI , the founder of this firm , is a very experienced professional with over 22 years of practical experience.

M/s V Ravi & Co., are providing audit, accounts and assurance services, Taxation and Legal Advisory Services, consultancy services. The team is well versed with corporate audits, internal audits, tax audits and sales tax audits, concurrent audits, stock audits and revenue audits and secretarial matters.

ARUNJYOTI BIO VENTURES LIMITED

M/s. V Ravi & Co., Chartered Accountants, have given their consent to the said appointment and confirmed that their appointment, if made, would be within the limits specified under Section 141(3)(g) of the Act. They have further confirmed that they are not disqualified to be appointed as statutory auditors in terms of the provisions of the proviso to Section 139(1), Section 141(2) and Section 141(3) of the Act and the provisions of the Companies (Audit and Auditors) Rules, 2014. Accordingly, as per the said requirements of the Act, M/s. V Ravi & Co., Chartered Accountants (Firm Registration No. 006492S) are proposed to be appointed as auditors for a period of 5 years, commencing from the conclusion of this 34th Annual General Meeting (AGM) until the conclusion of the 39th AGM, to the Members for their approval.

The Board of Directors recommends the Ordinary Resolution for approval of the Members. None of the Directors and Key Managerial Personnel of the Company or their relatives are concerned or interested financially or otherwise, in the resolution.

Disclosures made by the Company under Regulation 36(5) of SEBI (LODR) Regulations 2015, for seeking appointment of M/s. V Ravi & Co.,

S. No.	Particulars	Details
1.	Proposed Fees Payable	Rs. 100,000 p.a.
2.	Terms of Appointment	Five Years
3.	Basis of Recommendation for appointment/ Re-appointment	Audit Committee
4.	Credentials	As stated above

ITEM No. 4:

REAPPOINTMENT OF MR. VENKATRAMA RAO POLSANI AS INDEPENDENT DIRECTOR OF THE COMPANY

Mr. Venkatrama Rao Polsani (DIN 00129932) was appointed as Independent Director of the Company for a period of 5 years from 30th May 2016 up to 29th May, 2021, at the 30th Annual General Meeting held on 30th September 2016.

Mr. Venkatrama Rao Polsani's term as an Independent Director of the company ends on 29.05.2021. In terms of Section 149 and other applicable provisions of the Companies Act, 2013, Mr. Venkatrama Rao Polsani being eligible and offering himself for re-appointment as an Independent Director for five consecutive years w.e.f. 30.05.2021 to 29.05.2026. The Company has received a notice from a member under Section 160 of the Companies Act 2013 for appointment of Mr. Venkatrama Rao Polsani (DIN 00129932) for the office of Director in Independent category.

ARUNJYOTI BIO VENTURES LIMITED

In the opinion of the Board, Mr. Venkatrama Rao Polsani fulfils the conditions specified in the Companies Act, 2013 and rules made thereunder for his appointment as an Independent Director of the Company. The Board considers that his continued association would be of immense benefit to the Company and it is desirable to continue to avail services of Mr. Venkatrama Rao Polsani (DIN 00129932) as an Independent Director.

Accordingly the Board of Directors recommends the passing of the above resolution as Special Resolution set out in the item no. 4 of the notice for appointment of Mr. Venkatrama Rao Polsani.

Save and except Mr. Venkatrama Rao Polsani (DIN 00129932) Independent Director, being an appointee, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

ITEM No. 5:

REAPPOINTMENT OF MRS. VANAJA KUMARI DOKIPARTHI AS INDEPENDENT DIRECTOR OF THE COMPANY

Mrs. Vanaja Kumari Dokiparthi (DIN 07151205) was appointed as Independent Director of the Company for a period of 5 years up to 28th September, 2020 at the 29th Annual General Meeting held on 29th September 2015.

Mrs. Vanaja Kumari Dokiparthi term as an Independent Director of the company ends on 28.09.2020. In terms of Section 149 and other applicable provisions of the Companies Act, 2013, Mrs. Vanaja Kumari Dokiparthi being eligible and offering herself for re-appointment as an Independent Director for five consecutive years w.e.f. 29.09.2020 to 28.09.2025. The Company has received a notice from a member under Section 160 of the Companies Act 2013 for appointment of Mrs. Vanaja Kumari Dokiparthi (DIN 07151205) for the office of Director in Independent category.

In the opinion of the Board, Mrs. Vanaja Kumari Dokiparthi fulfils the conditions specified in the Companies Act, 2013 and rules made thereunder for her appointment as an Independent Director of the Company. The Board considers that her continued association would be of immense benefit to the Company and it is desirable to continue to avail services of Mrs. Vanaja Kumari Dokiparthi (DIN 07151205) as an Independent Director.

Accordingly the Board of Directors recommends the passing of the above resolution as Special Resolution set out in the item no. 5 of the notice for

ARUNJYOTI BIO VENTURES LIMITED

appointment of Mrs. Vanaja Kumari Dokiparthi

Save and except Mrs. Vanaja Kumari Dokiparthi (DIN 07151205) Independent Director, being an appointee, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Place: Secunderabad
Date: 04.12.2020**

**Sd/-
Rajakumar Babulal
Whole-time Director
(DIN: 07529064)**

ARUNJYOTI BIO VENTURES LIMITED

BOARDS' REPORT

Dear Members,

Your Directors have pleasure in presenting the Directors' Report and the Audited Statement of Accounts of the Company for the Financial Year ended 31st March 2020.

1. FINANCIAL SUMMARY/HIGHLIGHTS, OPERATIONS STATE OF AFFAIRS:

The performance of the Company during the year has been as under:

(In lakhs)

Particulars	2019-20	2018-19
Total Income	731.17	371.90
Total Expenditure	718.08	367.52
Profit Before Tax	13.09	4.38
Provision for Tax	2.52	NIL
Profit after Tax	10.57	4.38
Transfer to General Reserves	-	-
Profit available for appropriation	10.57	4.38
Provision for Proposed Dividend	-	-
Provision for Dividend Tax	-	-
Balance Carried to Balance Sheet	10.57	4.38
Basic EPS	0.51	0.21
Diluted EPS	0.51	0.21

REVIEW OF OPERATIONS:

Your Company has shown good results during the year under review and achieved sales and other income of Rs. 731.17 lakhs and net profit of Rs. 10.57 Lakhs as compared to sales and other income of Rs. 371.90 lakhs and net profit of Rs. 4.38 lakhs achieved in the previous financial year.

2. IMPACT OF COVID -19

The outbreak of Coronavirus pandemic globally and in India, in general, has disrupted significantly the economic activities across the world causing slowdown in economic growth. Due to outbreak of Coronavirus pandemic in India, Lock down imposed in India affects the total transport system, hence we are unable to dispatch our products (Mulching Sheets) to our customers in time.

Our office was operating in accordance with the statutory guidelines with respect to CoVID-19 ensuring health and safety of the employees.

3. CHANGE IN THE NATURE OF THE BUSINESS, IF ANY:

During the period under review and the date of Board's Report there was no change in the nature of Business.

4. RESERVES

During the year, your Company has not transferred any amount to General Reserve Account.

5. DIVIDEND

Keeping the Company's expansion and growth plans in mind, your directors have decided not to recommend dividend for the year.

6. UNPAID / UNCLAIMED DIVIDEND:

There is no unpaid or unclaimed dividend with the company.

7. MATERIAL CHANGES & COMMITMENT AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

There are no major material changes and commitments affecting the financial position of the Company after the end of the financial year and up to date of this report. (i.e. 28.07.2020)

8. REVISION OF FINANCIAL STATEMENTS:

There was no revision of the financial statements for the year under review.

9. BOARD MEETINGS:

The Board of Directors duly met Five (5) times during the financial year from 1st April 2019 to 31st March 2020. The dates on which the meetings were held are 30.05.2019, 13.08.2019, 12.11.2019, 03.01.2020 and 12.02.2020.

ARUNJYOTI BIO VENTURES LIMITED

10. APPOINTMENT / RE-APPOINTMENT / RESIGNATION / RETIREMENT OF DIRECTORS /CEO/ CFO AND KEY MANAGERIAL PERSONNEL:

- Mr. Romi Agarwal was resigned as company secretary and compliance officer with effect from 03.01.2020.
- Mr. Rama Mohan Challa, was appointed as Additional Director of Arunjyoti Bio Ventures Limited with effect from 15.12.2018. However, he did not wish to be reappointed as Director in the 33rd Annual General meeting and requested to relieve him as Director of the company after the conclusion of the AGM.
- Mr. P. Praveen Kumar (DIN: 02009879), who retires by rotation and being eligible, offers himself for re-appointment.
- Reappointment of Ms. Vanaja Kumari Dokaparthy as Independent Director of The Company for the term of 5 years.i.e. w.e.f. 30.09.2020 up to 29.09.2025.
- Reappointment of Mr. Venkata Rama Rao Polsani as an Independent Director of The Company for the term of 5 years.i.e. w.e.f. 30.05.2021 up to 29.05.2026.
- As required under regulation 36 (3) of the SEBI (LODR), Regulations, 2015, brief particulars of the Directors seeking appointment/re-appointment are given as under:-:

Name of the Director	Venkatrama Rao Polsani	Vanaja Kumari Dokiparthi	Mr. P. Praveen Kumar
Date of Birth	27.08.1957	07.09.1970	12.05.1976
Qualification	M.B.A.	Doctor	Graduate
Expertise in specific functional areas	Management	Technical	Technical
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board	-	1.Taaza International Limited 2.Grandma Trading & Agencies Ltd	1.Taaza International Limited 2.Grandma Trading & Agencies Ltd
Shareholding of non-executive directors.	-	-	-
No. of Shares held in the Company	-	-	1,03,664 Equity shares
Inter se relationship with any Director	-	-	-

11. DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS:

The Company has received declarations from Mrs. Vanaja Kumari Dokiparthi, Mr. MAditya Vardhan Reddy, Mr. Polsani Venkata Rama Rao and Mr. Chandra Shekar Kondari Independent Directors of the Company to the effect that they are meeting the criteria of independence as provided in Sub-Section (6) of Section 149 of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

12. FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS:

Independent Directors are familiarized about the Company's operations and businesses. Interaction with the Business heads and key executives of the Company is also facilitated. Detailed presentations on important policies of the Company is also made to the directors.

The details of familiarisation programme held in FY 2019-20 are also disclosed on the Company's website at [https:// www.orbisagri.com](https://www.orbisagri.com)

13. POLICY ON DIRECTOR'S APPOINTMENT AND REMUNERATION AND OTHER DETAILS:

The assessment and appointment of Members to the Board is based on a combination of criterion that includes ethics, personal and professional stature, domain expertise, gender diversity and specific qualification required for the position. The potential Board Member is also assessed on the basis of independence criteria defined in Section 149(6) of the Companies Act, 2013 and Regulation 27 of SEBI (LODR) Regulations, 2015.

In accordance with Section 178(3) of the Companies Act, 2013, and Regulation 19(4) of SEBI (LODR) Regulations, 2015, on the recommendations of the Nomination and Remuneration Committee, the Board adopted a remuneration policy for Directors, Key Management Personnel (KMPs) and Senior Management. The Policy is included in the Directors Report elsewhere.

14. NON-EXECUTIVE DIRECTORS' COMPENSATION AND DISCLOSURES:

None of the Independent / Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgment of the Board may affect the independence of the Directors.

15. COMPOSITION OF COMMITTEES:

AUDIT COMMITTEE: (Audit Committee constituted in terms of sec. 177 of Companies Act, 2013 read with reg. 18 of SEBI (LODR) Regulations, 2015)

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE:

The terms of reference of the Audit Committee encompasses the requirements of Section 177 of Companies Act, 2013 and as per Regulation 18 of SEBI (LODR) Regulations, 2015 and, interalia, includes

1. Over view of the Company's financial reporting process and disclosure of its financial information to ensure that the financial statement reflects a true and fair position and that sufficient and credible information is disclosed.
2. Recommending the appointment and removal of statutory auditors, internal auditors and cost auditors, fixation of their audit fees and approval for payment of any other services.
3. Discussion with external auditors before the audit commences, of the nature and scope of audit as well as post-audit discussion to ascertain any area of concern.
4. Reviewing the financial statement and draft audit report, including quarterly/half yearly financial information.
5. Reviewing with the management the annual financial statements before submission to the Board, focusing primarily on:
 - i) Any changes in accounting policies and practices.
 - ii) Major accounting entries based on excises of judgment by the management.
 - iii) Qualifications in draft audit report.
 - iv) Significant adjustment arises out of audit.
 - v) The going concern assumption.
 - vi) Compliance with accounting standards, stock exchange and legal requirement concerning financial statements.
 - vii) Review and approval of related party transactions.

ARUNJYOTI BIO VENTURES LIMITED

6. Reviewing the company's financial and risk management's policies.
7. Disclosure of contingent liabilities.
8. Reviewing with management, external and internal auditors, the adequacy of internal control systems.
9. Reviewing the adequacy of internal audit function, including the audit character, the structure of the internal audit department, approval of the audit plan and its execution, staffing and seniority of the official heading the department, reporting structure, coverage and frequency of internal audit.
10. Discussion with internal auditors of any significant findings and follow-up thereon.
11. Reviewing the findings of any internal investigations by the internal auditors into the matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board.
12. Looking into the reasons for substantial defaults in payments to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors.
13. Reviewing compliances as regards the Company's Whistle Blower Policy.
14. Review and monitor the end use of funds raised through public offers and related matters;
15. Approval of appointment of Chief Financial Officer after assessing the qualifications, experience and background, etc. of the candidate;
16. Frame and review policies in relation to implementation of the Code of Conduct for Prevention of Insider Trading and supervise its implementation under the overall supervision of the Board;
17. Discharge such duties and functions as indicated in the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Companies Act, 2013 and the rules made thereunder from time to time.
18. reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision.

ARUNJYOTI BIO VENTURES LIMITED

B. COMPOSITION, MEETINGS & ATTENDANCE

There were four (4) Audit Committee Meetings held during the year on 30.05.2019, 13.08.2019, 12.11.2019 and 12.02.2020.

Name	Designation	Category	No. of meetings held	No. of meeting attended
M Aditya Vardhan Reddy	Chairman	NED(I)	4	4
Vanaja Kumari Dokiparthi	Member	NED(I)	4	4
Mr. Raja Kumar Babulal	Member	ED	4	4

NED (I): Non Executive Independent Director

ED: Executive Director

- C. The previous Annual General Meeting of the Company was held on 30.09.2019 and Chairman of the Audit Committee, attended previous AGM.

NOMINATION & REMUNERATION COMMITTEE

The terms of reference of the Nomination and Remuneration committee constituted in terms of Section 178 of Companies Act, 2013 and as per Regulation 19 of SEBI (LODR) Regulations, 2015 are as under:

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE

- To approve the fixation/revision of remuneration of Executive Directors of the Company and while approving:
 - a. To take into account the financial position of the Company, trend in the industry, appointee's qualification, experience, past performance, past remuneration etc.
 - b. To bring out objectivity in determining the remuneration package while striking a balance between the interest of the Company and the Shareholders.
- To identify persons who are qualified to become Directors and who may be appointed in senior management in accordance with the criteria laid down and to recommend to the Board their appointment and /or removal.
- To carry out evaluation of every Director's performance.
- To formulate the criteria for determining qualifications, positive attributes and independence of a Director, and recommend to the Board a policy,

ARUNJYOTI BIO VENTURES LIMITED

relating to the remuneration for the Directors, key managerial personnel and other employees.

- To formulate the criteria for evaluation of Independent Directors and the Board.
- To recommend/review remuneration of the Managing Director and Whole-time Director(s) based on their performance and defined assessment criteria.
- Recommend to the board, all remuneration, in whatever form, payable to senior management.
- On an annual basis, recommend to the Board the remuneration payable to Directors, KMP and executive team of the Company.
- Review matters related to remuneration and benefits payable upon retirement and severance to MD/EDs, KMP and executive team.
- Review matters related to voluntary retirement and early separation schemes for the Company.
- Provide guidelines for remuneration of Directors on material subsidiaries.
- Recommend to the Board how the Company will vote on resolutions for remuneration of Directors on the Boards of its material subsidiaries.
- Assist the Board in fulfilling its corporate governance responsibilities relating to remuneration of the Board, KMP and executive team members.
- Oversee familiarization programmes for Directors.
- Review HR and People strategy and its alignment with the business strategy periodically, or when a change is made to either.
- Review the efficacy of HR practices, including those for leadership development, rewards and recognition, talent management and succession planning.
- Perform other activities related to the charter as requested by the Board from time to time

ARUNJYOTI BIO VENTURES LIMITED

B. COMPOSITION OF THE COMMITTEE, MEETINGS & ATTENDANCE

There were two Nomination and Remuneration Committee Meetings held during the financial year on 30.05.2019, 12.02.2020

Name	Designation	Category	No. of meetings held	No. of meeting attended
M Aditya Vardhan Reddy	Chairman	NED(I)	2	2
Vanaja Kumari Dokiparthi	Member	NED(I)	2	2
Polsani Venkata Rama Rao	Member	NED(I)	2	2

NED (I): Non Executive Independent Director

ED: Executive Director

Remuneration Policy:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit.

The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered, individual performance etc.

Remuneration paid to Mr. P. Praveen Kumar is Rs. 9,50,000 in the financial year 2019-20

None of the Directors is drawing any Commission, Perquisites, Retirement benefits etc.,

POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS' INDEPENDENCE

1. Scope:

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

2. Terms and References:

2.1 "Director" means a director appointed to the Board of a Company.

ARUNJYOTI BIO VENTURES LIMITED

- 1.2 “Nomination and Remuneration Committee means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and reg. 19 of SEBI (Listing Obligation and Disclosure Requirement), Regulations, 2015.
- 2.3 “Independent Director” means a director referred to in sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 16(1) (b) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

Qualifications and criteria

- 3.1.1 The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a board with diverse background and experience that are relevant for the Company's operations.
- 3.1.2 In evaluating the suitability of individual Board member the NR Committee may take into account factors, such as:
- General understanding of the company's business dynamics, global business and social perspective;
 - Educational and professional background
 - Standing in the profession;
 - Personal and professional ethics, integrity and values;
 - Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.
- 3.1.3 The proposed appointee shall also fulfil the following requirements:
- shall possess a Director Identification Number;
 - shall not be disqualified under the Companies Act, 2013;
 - shall Endeavour to attend all Board Meeting and Wherever he is appointed as a Committee Member, the Committee Meeting;
 - shall abide by the code of Conduct established by the company for Directors and senior Management personnel;

ARUNJYOTI BIO VENTURES LIMITED

- shall disclose his concern or interest in any company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;
- Such other requirements as may be prescribed, from time to time, under the Companies Act, 2013, SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 and other relevant laws.

3.1.4 The Nomination & Remuneration Committee shall evaluate each individual with the objective of having a group that best enables the success of the company's business.

3.2 criteria of independence

3.2.1 The Nomination & Remuneration Committee shall assess the independence of Directors at time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or relationships are disclosed by a Director.

3.2.2 The criteria of independence shall be in accordance with guidelines as laid down in Companies Act, 2013 and reg. 16(1) (b) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.

3.2.3 The Independent Director shall abide by the "Code for Independent Directors" as specified in Schedule IV to the companies Act, 2013.

1.3 Other Directorships/ Committee Memberships

3.3.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance Accordingly, members should voluntarily limit their directorships in other listed public limited companies in such a way that it does not interfere with their role as Director of the company. The NR Committee shall take into account the nature of, and the time involved in a Director service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.

3.3.2 A Director shall not serve as director in more than 20 companies of which not more than 10 shall be public limited companies.

3.3.3 A Director shall not serve an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed company.

ARUNJYOTI BIO VENTURES LIMITED

3.3.4 A Director shall not be a member in more than 10 committee or act chairman of more than 5 committee across all companies in which he holds directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under section 8 of the Companies Act, 2013 shall be excluded.

Remuneration policy for Directors, key managerial personnel and other employees

1. **Scope:**

1.1 This policy sets out the guiding principles for the Nomination and Remuneration committee for recommending to the Board the remuneration of the directors, key managerial personnel and other employees of the company.

2. **Terms and Reference:**

In this policy the following terms shall have the following meanings:

2.1 "Director" means a Director appointed to the Board of the company.

2.2 "key managerial personnel" means

(i) The Chief Executive Office or the managing director or the manager;

(ii) The company secretary;

(iii) The whole-time director;

(iv) The chief finance Officer; and

(v) Such other office as may be prescribed under the companies Act, 2013

2.3 "Nomination and Remuneration Committee" means the committee constituted by Board in accordance with the provisions of section 178 of the companies Act, 2013 and reg. 19 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.

3. **Policy:**

3.1 Remuneration to Executive Director and Key Managerial Personnel

ARUNJYOTI BIO VENTURES LIMITED

- 3.1.1 The Board on the recommendation of the Nomination and Remuneration (NR) committee shall review and approve the remuneration payable to the Executive Director of the company within the overall approved by the shareholders.
- 3.1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the company.
- 3.1.3 The Remuneration structure to the Executive Director and key managerial personnel shall include the following components:
- (i) Basic pay
 - (ii) Perquisites and Allowances
 - (iii) Commission (Applicable in case of Executive Directors)
 - (iv) Retirement benefits
 - (v) Annual performance Bonus
- 3.1.4 The Annual plan and Objectives for Executive committee shall be reviewed by the NR committee and Annual performance Bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.

3.2 Remuneration to Non – Executive Directors

- 3.2.1 The Board, on the recommendation of the Nomination and Remuneration Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders as per provisions of the companies act.
- 3.2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof.
- 3.3. Remuneration to other employees
- 3.3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

C. REMUNERATION POLICY:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit.

The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered and individual performance.

POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS' INDEPENDENCE:

1. Scope:

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

2. Terms and References:

- 2.1 "Director" means a Director appointed to the Board of a Company.
- 2.2 "Nomination and Remuneration Committee means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2.3 "Independent Director" means a Director referred to in sub-Section (6) of Section 149 of the Companies Act, 2013 and Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

Qualifications and criteria

- 3.1.1 The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a board with diverse background and experience that are relevant for the Company's operations.
- 3.1.2 In evaluating the suitability of individual Board member the NR Committee may take into account factors, such as:

ARUNJYOTI BIO VENTURES LIMITED

- General understanding of the Company's business dynamics, global business and social perspective;
- Educational and professional background
- Standing in the profession;
- Personal and professional ethics, integrity and values;
- Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.

3.1.3 The proposed appointee shall also fulfill the following requirements:

- shall possess a Director Identification Number;
- shall not be disqualified under the companies Act, 2013;
- shall Endeavour to attend all Board Meeting and Wherever he is appointed as a Committee Member, the Committee Meeting;
- shall abide by the code of Conduct established by the Company for Directors and senior Management personnel;
- shall disclose his concern or interest in any Company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;
- Such other requirements as any prescribed, from time to time, under the companies Act, 2013, Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other relevant laws.

3.1.4 The Nomination & Remuneration Committee shall evaluate each individual with the objective of having a group that best enables the success of the Company's business.

3.2 Criteria of Independence

3.2.1 The Nomination & Remuneration Committee shall assess the independence of Directors at time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or relationships are disclosed by a Director.

ARUNJYOTI BIO VENTURES LIMITED

3.2.2 The criteria of independence shall be in accordance with the guidelines as laid down in Companies Act, 2013 and Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

An independent Director in relation to a Company, means a Director other than a managing Director or a whole-time Director or a nominee Director-

- a. who, in the opinion of the Board, is a person of integrity and possesses relevant expertise and experience;
- b. (i) who is or was not a promoters of the Company or its holding, subsidiary or associate Company;
(ii) who is not related to promoters or Directors of the Company its holding, subsidiary or associate Company
- c. who has or had no pecuniary relationship with the Company, its holding, subsidiary or associate Company, or their promoters, or Director, during the two immediately preceding financial year or during the current financial year;
- d. none of whose relative has or had pecuniary relationship or transaction with the Company, its holding, subsidiary or associate Company, or their promoters, or Directors, amounting to two per cent or more of its gross turnover or total income or fifty lakh rupees or such higher amount as may be prescribed, whichever is lower, during the two immediately preceding financial year or during the current finance year;
- e. who, neither himself nor any of his relative-
 - (i) Holds or has held the position of a key managerial personnel or is or has been employee of the or associate Company in any of the three finance years immediately preceding the finance year in which he is proposed to be appointed;
 - (ii) Is or has been an employee or proprietor or a partner, in any of the three finance year immediately preceding the financial year in which he is proposed to be appointed of-
 - (A) a firm of auditors or Company secretaries in practice or cost auditors of the Company or its holding, subsidiary or associate Company; or
 - (B) any legal or a consulting firm that has or had any transaction with the Company, its holding subsidiary or associate Company amounting to ten per cent or more of the gross turnover of more of the gross turnover of such firm;

ARUNJYOTI BIO VENTURES LIMITED

- (i) holds together with his relatives two per cent or more of the total voting power of the Company; or
 - (ii) is a chief Executive or Director, by whatever name called, of any non-profit organization that receives twenty-five per cent or more of its receipt from the Company any of its promoters, Directors or its holding subsidiary or associate Company or that holds two per cent or more of the total voting power of the Company; or
 - (iii) is a material supplier, service provider or customer or a lesser or lessee of the Company.
- f. Shall possess appropriate skills experience and knowledge in one or more field of finance, law management, sales, marketing administration, research, corporate governance, technical operations, corporate social responsibility or this disciplines related to the Company's business.
- g. Shall possess such other qualifications as may be prescribed from time to time, under the Companies Act, 2013.
- h. who is not less than 21 years of age

3.2.3 The independent Director shall abide by the "code for independent Directors" as specified in Schedule IV to the companies Act, 2013.

3.3 Other Directorships/ Committee Memberships

3.3.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance Accordingly, members should voluntarily limit their Directorships in other listed public limited companies in such a way that it does not interfere with their role as Director of the Company. The NR Committee shall take into account the nature of, and the time involved in a director service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.

3.3.2 A Director shall not serve as Director in more than 20 companies of which not more than 10 shall be public limited companies.

3.3.3 A Director shall not serve an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed Company.

3.3.4 A Director shall not be a member in more than 10 committee or act as chairman of more than 5 committee across all companies in which he holds Directorships.

ARUNJYOTI BIO VENTURES LIMITED

For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under Section 8 of the companies Act, 2013 shall be excluded.

Remuneration policy for Directors, key managerial personnel and other employees:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit.

The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered and individual performance.

Remuneration policy for Directors, key managerial personnel and other employees

1. Scope:

- 1.1 This policy sets out the guiding principles for the Nomination and Remuneration committee for recommending to the Board the remuneration of the Directors, key managerial personnel and other employees of the Company.

2. Terms and Reference:

In this policy the following terms shall have the following meanings:

- 2.1 "Director" means a Director appointed to the Board of the Company.
- 2.2 "key managerial personnel" means
 - (i) The Chief Executive Officer or the managing Director or the manager;
 - (ii) The Company Secretary;
 - (iii) The Whole-time Director;
 - (iv) The Chief Financial Officer; and
 - (v) Such other office as may be prescribed under the companies Act, 2013

ARUNJYOTI BIO VENTURES LIMITED

2.3 “Nomination and Remuneration committee” means the committee constituted by Board in accordance with the provisions of Section 178 of the companies Act, 2013, clause 49 of the Equity Listing Agreement and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

3.1 Remuneration to Executive Director and key managerial personnel

3.1.1 The Board on the recommendation of the Nomination and Remuneration (NR) committee shall review and approve the remuneration payable to the Executive Director of the Company within the overall approved by the shareholders.

3.1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the Company.

3.1.3 The remuneration structure to the Executive Director and key managerial personnel shall include the following components:

(i) Basic pay

(ii) Perquisites and Allowances

(iii) Stock Options

(iv) Commission (Applicable in case of Executive Directors)

(v) Retrial benefits

(vi) Annual performance Bonus

3.1.4 The Annual plan and Objectives for Executive committee shall be reviewed by the NR committee and Annual performance bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.

3.2 Remuneration to Non – Executive Directors

3.2.1 The Board, on the recommendation of the NR Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders as per the provisions of the Companies Act.

3.2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof. The Non-Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.

3.3. Remuneration to other employees

3.3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

D. MECHANISM FOR EVALUATION OF THE BOARD

Evaluation of all Board members is performed on an annual basis. The evaluation is performed by the Board, Nomination and Remuneration Committee and Independent Directors with specific focus on the performance and effective functioning of the Board and Individual Directors.

In line with Securities and Exchange Board of India Circular No.SEBI/HO/CFD/CMD/CIR/P/2017/004, dated January 5, 2017 and the Companies Amendment Act, 2017 the Company adopted the recommended criteria by Securities and Exchange Board of India.

The Directors were given six Forms for evaluation of the following:

- (i) Evaluation of Board;
- (ii) Evaluation of Committees of the Board;
- (iii) Evaluation of Independent Directors;
- (iv) Evaluation of Chairperson;
- (v) Evaluation of Non-Executive and Non-Independent Directors; and
- (vi) Evaluation of Managing Director.

The Directors were requested to give following ratings for each criteria:

- 1. Could do more to meet expectations;
- 2. Meets expectations; and
- 3. Exceeds expectations.

ARUNJYOTI BIO VENTURES LIMITED

The Directors have sent the duly filled forms to Nomination & Remuneration committee. Based on the evaluation done by the Directors, the Committee has prepared a report and submitted the Evaluation Report. Based on the report, the Board of Directors has informed the rankings to each Director and also informed that the performance of Directors is satisfactory and they are recommended for continuation as Directors of the Company.

4. STAKEHOLDERS RELATIONSHIP COMMITTEE:

During the year April 2019 to March 2020, One (1) Stakeholders Relationship Committee Meetings were held. The said meeting was held on 13.02.2020

A. COMPOSITION AND ATTENDANCE FOR MEETINGS:

Name	Designation	Category	No. of meetings held	No. of meeting attended
M Aditya Vardhan Reddy	Chairman	NED(I)	1	1
Polsani Venkata Rama Rao	Member	NED(I)	1	1
Raja Kumar Babulal	Member	ED	1	1

NED (I): Non Executive Independent Director

ED: Executive Director

B) Powers:

The Committee has been delegated with the following powers:

- To redress shareholder and investor complaints relating to transfer of shares, Dematerialization of Shares, non-receipt of Annual Reports, non-receipt of declared dividend and other allied complaints.
- To approve, transfer, transmission, and issue of duplicate / fresh share certificate(s)
- Consolidate and sub-division of share certificates etc.
- To redress, approve and dispose off any, other complaints, transactions and requests etc., received from any shareholder of the company and investor in general.

The Board has delegated the power to process the transfer and transmission of shares to the Registrar and Share Transfer Agents, who

ARUNJYOTI BIO VENTURES LIMITED

process share transfers within a week of lodgement in the case of shares held in physical form.

The Company has designated an exclusive e-mail ID called cenport@gmail.com for complaints/grievances.

VII. RISK MANAGEMENT COMMITTEE

The Committee's prime responsibility is to implement and monitor the risk management plan and policy of the Company. The Committee's constitution meets with the requirements of Regulation 21 of SEBI (LODR) Regulations, 2015

A. ROLE AND RESPONSIBILITIES OF THE COMMITTEE INCLUDES THE FOLLOWING:

- Framing of Risk Management Plan and Policy
- Overseeing implementation of Risk Management Plan and Policy
- Monitoring of Risk Management Plan and Policy
- Validating the process of risk management
- Validating the procedure for Risk minimisation
- Periodically reviewing and evaluating the Risk Management Policy and practices with respect to risk assessment and risk management processes.
- Continually obtaining reasonable assurance from management that all known and emerging risks have been identified and mitigated or managed.

B. COMPOSITION

The composition of the Risk Management Committee as under:

Name	Designation	Category
Vanaja Kumari Dokiparthi	Chairperson	NED(I)
M Aditya Vardhan Reddy	Member	NED(I)
Raja Kumar Babulal	Member	ED

NED (I) : Non Executive Independent Director

ED: Executive Director

No meeting held during the year 2019-20

16. DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the requirement of Section 134(3)(C) and 134(5) of the Companies Act, 2013 and on the basis of explanation given by the executives of the Company and subject to disclosures in the Annual Accounts of the Company from time to time, we state as under:

1. That in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
2. That the Directors have selected such accounting policies and applied them consistently and made judgment and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that period;
3. That the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
4. That the Directors have prepared the annual accounts on a going concern basis;
5. That the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and
6. That the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

17. INVESTOR EDUCATION AND PROTECTION FUND (IEPF):

During the year, no amount was transferred to Investor Education and Protection Fund (IEPF).

18. INFORMATION ABOUT THE FINANCIAL PERFORMANCE / FINANCIAL POSITION OF THE SUBSIDIARIES / ASSOCIATES/ JOINT VENTURES:

During the year under review, the Company does not have any subsidiaries, joint ventures or associate Companies.

19. EXTRACT OF ANNUAL RETURN:

As required pursuant to Section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014, an extract of annual return in MGT 9 is a part of this Annual Report in enclosed as Annexure-I.

20. STATUTORY AUDITORS:

M/s. M.M. Reddy & Co, Chartered Accountants, the present Auditors of the Company complete their term as Auditors and in terms of their appointment made they are holding office of the auditors up to the conclusion of the 34th AGM and hence, would retire at the conclusion of the forthcoming 34th AGM.

M/S M.M Reddy & Co has provided the Auditors Report along with notes to accounts for the Financial Year ended 31.03.2020

21. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB SECTION (12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL GOVERNMENT:

There have been no frauds reported by the auditors u/s 143(12).

22. INTERNAL AUDITORS:

During the Year, no internal Auditor was appointed.

23. DISCLOSURE ABOUT COST AUDIT:

Cost Audit is not applicable to your Company.

24. SECRETARIAL AUDITOR:

Pursuant to the provisions of Section 134(3) (f) & Section 204 of the Companies Act, 2013, the Board has appointed M/s. Vivek Surana & Associates, Practicing Company Secretaries to undertake Secretarial Audit of the Company for financial year ending 31.03.2020. The report of the Secretarial Auditor is enclosed herewith vide Annexure-II of this Report.

25. QUALIFICATIONS IN AUDIT REPORTS:

Explanations or comments by the Board on every qualification, reservation or adverse remark or disclaimer made—

(a) Statutory Auditors Report:

The Board has duly reviewed the Statutory Auditor's Report on the

ARUNJYOTI BIO VENTURES LIMITED

Accounts for the year ended March 31, 2020 and has noted that the same does not have any reservation, qualification or adverse remarks. However, the Board decided to further strengthen the existing system and procedures to meet all kinds of challenges and growth in the market expected in the coming years.

(b) Secretarial Audit Report:

The Board has duly reviewed the Secretarial Audit Report for the year ended March 31, 2020 on the Compliances according to the provisions of Section 204 of the Companies Act 2013, and the same does not have any reservation, qualifications or adverse remarks except that the Company does not have an Internal Auditor.

Reply:

The Company is in the process of appointment of Internal Auditor.

26. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

The Company has not given loans, Guarantees or made any investments during the year under review which attracts the provisions of Section 186 of the Companies Act, 2013

27. RELATED PARTY TRANSACTIONS:

All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of business. There were no material significant related party transactions made by the Company with the Promoters, Directors, Key Managerial Personnel or the Senior Management which may have a potential conflict with the interest of the Company at large.

All related party transactions were placed before the Audit Committee/Board for approval. Prior approval of the Audit Committee was obtained for the transactions which are foreseen and are in repetitive in nature.

The Company has not entered into any contracts/arrangements with related parties referred to Section 188(1) of the Companies Act, 2013 except certain arm length transaction during the year. Accordingly no disclosure or reporting is required covered under this Section.

28. NAMES OF THE COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR:

During the year under review no Company has become or ceased to become its subsidiaries, joint ventures or associate Company.

29. DISCLOSURE OF PARTICULARS WITH RESPECT TO CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

The required information as per Sec.134 (3) (m) of the Companies Act 2013 is provided hereunder:

A. Conservation of Energy:

Your Company's operations are not energy intensive. Adequate measures have been taken to conserve energy wherever possible by using energy efficient computers and purchase of energy efficient equipment.

B. Technology Absorption:

1. Research and Development (R&D): NIL
2. Technology absorption, adoption and innovation: NIL

C. Foreign Exchange Earnings and Out Go:

Foreign Exchange Earnings : NIL

Foreign Exchange Outgo : NIL

30. VIGIL MECHANISM/WHISTLE BLOWER POLICY:

In pursuant to the provisions of Section 177(9) & (10) of the Companies Act, 2013, a vigil Mechanism for Directors and employees to report genuine concerns has been established. It also provides for necessary safeguards for protection against victimization for whistle blowing in good faith.

Vigil Mechanism Policy has been established by the Company for directors and employees to report genuine concerns pursuant to the provisions of section 177(9) & (10) of the Companies Act, 2013. The same has been placed on the website of the Company.

31. CORPORATE SOCIAL RESPONSIBILITY (CSR, COMPOSITION OF CSR COMMITTEE AND CONTENTS OF CSR POLICY):

Since the Company does not have the net worth of Rs. 500 Crore or more, or turnover of Rs. 1000 Crore or more, or a net profit of Rs. 5 Crore or more during the financial year, section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility is not applicable and hence the Company need not adopt any Corporate Social Responsibility Policy.

32. PUBLIC DEPOSITS:

Your Company has not accepted any deposits falling within the meaning of Sec 73, 74 & 76 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules 2014, during the financial year under review.

33. SIGNIFICANT & MATERIAL ORDERS PASSED BY COURTS / REGULATORS / TRIBUNALS:

There are no significant and material orders passed by the regulators / courts that would impact the going concern status of the Company and its future operations.

34. DISCLOSURE OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS:

The Internal Financial Controls with reference to financial statements as designed and implemented by the Company are adequate. The Company maintains appropriate system of internal control, including monitoring procedures, to ensure that all assets are safeguarded against loss from unauthorized use or disposition. Company policies, guidelines and procedures provide for adequate checks and balances, and are meant to ensure that all transactions are authorized, recorded and reported correctly.

During the period under review, there is no material or serious observations have been noticed for inefficiency or inadequacy of such controls.

35. INSURANCE:

The Company does not have any major fixed assets and accordingly it is not required to take any insurance policy.

36. CREDIT & GUARANTEE FACILITIES:

The Company has not availed any facilities of Credit and Guarantee, for the business of the Company.

37. SHARE CAPITAL

The authorised share capital of the Company stands at Rs. 3,50,00,000/-

The paid up share capital of the Company stands at Rs. 2,07,09,000 /- divided into 20,70,900 equity shares of Rs. 10/- each.

38. CORPORATE GOVERNANCE AND SHAREHOLDERS INFORMATION:

Since the paid up capital of the Company is less than Rs. 10 Crores and Net worth of the Company is less than Rs. 25 Crores, Corporate Governance as envisaged in SEBI LODR Regulations is not applicable.

39. MANAGEMENT DISCUSSIONS AND ANALYSIS REPORT:

The Management Discussion and Analysis Report, pursuant to the SEBI (LODR) Regulation appended as Annexure III for information of the Members.

40. POLICIES:

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies for all listed companies. All the policies are available on our website (<https://www.orbisagri.com>). The policies are reviewed periodically by the Board and updated based on need and new compliance requirement.

41. CORPORATE INSOLVENCY RESOLUTION PROCESS INITIATED UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (IBC):

There is no application filed for corporate insolvency resolution process, by a financial or operational creditor or by the company itself under the IBC before the NCLT.

42. ENVIRONMENTS AND HUMAN RESOURCE DEVELOPMENT:

Your Company always believes in keeping the environment pollution free and is fully committed to its social responsibility. The Company has been taking utmost care in complying with all pollution control measures from time to time strictly as per the directions of the Government.

ARUNJYOTI BIO VENTURES LIMITED

We would like to place on record our appreciation for the efforts made by the management and the keen interest shown by the Employees of your Company in this regard.

43. STATUTORY COMPLIANCE:

The Company has complied with the required provisions relating to statutory compliance with regard to the affairs of the Company in all respects.

44. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013. The following is the summary of sexual harassment complaints received and disposed during the calendar year.

- No. of complaints received: Nil
- No. of complaints disposed off: Nil

45. STATEMENT SHOWING THE NAMES OF THE TOP TEN EMPLOYEES IN TERMS OF REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE AS PER RULE 5(2) & (3) OF THE COMPANIES (APPOINTMENT & REMUNERATION) RULES, 2014:

A table containing the particulars in accordance with the provisions of Section 197(12) of the Act, read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is appended as Annexure IV to this Report.

A statement showing the names of the top ten employees in terms of remuneration drawn and the name of every employee is annexed to this Annual report as Annexure V

During the year NONE of the employees is drawing a remuneration of Rs.1,02,00,000/- and above per annum or Rs.8,50,000/- and above in aggregate per month, the limits specified under the Section 197(12) of the Companies Act, 2013 read with Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

46. RATIO OF REMUNERATION TO EACH DIRECTOR

Under section 197(12) of the Companies Act, 2013, and Rule 5(1) (2) &

(3) of the Companies (Appointment & Remuneration) Rules, 2014 read with Schedule V of the Companies Act, 2013 the ratio of remuneration of Mr. Pabbathi Praveen Kumar, Whole-time Director of the Company to the median remuneration of the employees is 4.87:1

47. CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING:

The Board of Directors has adopted the Insider Trading Policy in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulation, 2015. The Insider Trading Policy of the Company lays down guidelines and procedures to be followed, and disclosures to be made while dealing with shares of the Company, as well as the consequences of violation. The policy has been formulated to regulate, monitor and ensure reporting of deals by employees and to maintain the highest ethical standards of dealing in Company securities.

The Insider Trading Policy of the Company covering code of practices and procedures for fair disclosure of unpublished price sensitive information and code of conduct for the prevention of insider trading, is available on our website www.orbisagri.com

48. SECRETARIAL STANDARDS

The Company is in compliance with the applicable secretarial standards.

49. EVENT BASED DISCLOSURES

During the year under review, the Company has not taken up any of the following activities:

1. Issue of sweat equity share: NA
2. Issue of shares with differential rights: NA
3. Issue of shares under employee's stock option scheme: NA
4. Disclosure on purchase by Company or giving of loans by it for purchase of its shares: NA
5. Buy back shares: NA
6. Disclosure about revision: NA
7. Preferential Allotment of Shares: NA

50. CEO/ CFO Certification

The Managing Director cum CEO and CFO certification of the financial statements for the year 2019-2020 is annexed in this Annual Report.

51. ACKNOWLEDGEMENTS:

Your Directors wish to place on record their appreciation of the contribution made by the employees at all levels, to the continued growth and prosperity of your Company. Your Directors also wish to place on record their appreciation of business constituents, banks and other financial institutions and shareholders of the Company for their continued support for the growth of the Company.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Place: Secunderabad
Date: 28.07.2020**

**Sd/-
Pabbathi Praveen Kumar
Whole-time Director cum CFO
(DIN: 02009879)**

**Sd/-
Rajakumar Babulal
Whole-time Director
(DIN: 07529064)**

ARUNJYOTI BIO VENTURES LIMITED

CERTIFICATE OF CODE OF CONDUCT FOR THE YEAR 2019-20

The shareholders,

Code of Conduct

The Company has formulated and implemented a Code of Conduct for Board Members and Senior Management of the Company. Requisite annual affirmations of compliance with the respective Codes have been made by the Directors and Senior Management of the Company.

Certificate of Code of Conduct for the year 2019-2020 as per Regulation 17(5) read with Regulation 34 (3) Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Arunjyoti Bio Ventures Limited is committed for conducting its business in accordance with the applicable laws, rules and regulations and with highest standards of business ethics. The Company has adopted a "Code of Ethics and Business Conduct" which is applicable to all Director, officers and employees.

I hereby certify that all the Board Members and Senior Management have affirmed the compliance with the Code of Ethics and Business Conduct, under a certificate of Code of Conduct for the year 2019-2020.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

Place: Secunderabad
Date: 28.07.2020

Sd/-
Pabbathi Praveen Kumar
Whole-time Director cum CFO
(DIN: 02009879)

Sd/-
Rajakumar Babulal
Whole-time Director
(DIN: 07529064)

ARUNJYOTI BIO VENTURES LIMITED

ANNEXURE - I

FORM NO. MGT – 9

EXTRACT OF ANNUAL RETURN

as on the financial year ended on 31st March, 2020

[Pursuant to Section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

i)	CIN	L01400TG1986PLC062463
ii)	Registration Date	27.02.1986
iii)	Name of the Company	M/s. Arunjyoti Bio Ventures Limited (formerly Century 21 st Portfolio Limited)
iv)	Category / Sub-Category of the Company	Company limited by shares/ Non-Government Company
v)	Address of the Registered office and contact details	Plot No. 45, P & T colony, Kharkhana Road, Secunderabad – 500009, Telangana.
vi)	Whether Listed Company	Yes
vii)	Name, Address and Contact details of Registrar and Share Transfer Agent, if any	M/s. Venture Capital And Corp. Invest. Pvt. Ltd. 12-10-167, Bharat Nagar Hyderabad - 500 018 Ph. No. 040-23818475/23818476/23868023 Fax : +91 040-23868024.

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turnover of the Company shall be stated:-

Sl. No.	Name and Description of main products / services	NIC Code of the Product / service	% to total turnover of the Company
1	Purchase and sale of fertilizers	46692	100

II. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

S. No	Name and Address of the Company	CIN/GLN	Holding / Subsidiary / Associate	% of shares held	Applicable Section
	NA	NA	NA	NA	NA

ARUNJYOTI BIO VENTURES LIMITED

IV.SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoter									
(1) Indian									
a) Individual / HUIF	188491	--	188491	9.10	188491	--	188491	9.10	--
b) Central Govt	--	--	--	--	--	--	--	--	--
c) State Govt (s)	--	--	--	--	--	--	--	--	--
d) Bodies Corp	--	--	--	--	--	--	--	--	--
e) Banks / FI's	--	--	--	--	--	--	--	--	--
f) Any Other	--	--	--	--	--	--	--	--	--
Sub Total (A) (1)	188491	--	188491	9.10	188491	--	188491	9.10	--
(2) Foreign	--	--	--	--	--	--	--	--	--
a) NRI Individuals	--	--	--	--	--	--	--	--	--
b) Other Individuals	--	--	--	--	--	--	--	--	--
c) Bodies Corporate	--	--	--	--	--	--	--	--	--
d) Banks / FI	--	--	--	--	--	--	--	--	--
e) Any Other	--	--	--	--	--	--	--	--	--
Sub Total (A) (2)	--	--	--	--	--	--	--	--	--
Total Shareholding of Promoter (A)=(A)(1) + (A)(2)	188491	--	188491	9.10	188491	--	188491	9.10	--
B. PUBLIC SHAREHOLDING									
1. Institutions									
a) Mutual Funds	--	--	--	--	--	--	--	--	--
b) Banks / FI	--	--	--	--	--	--	--	--	--
c) Central Govt	--	--	--	--	--	--	--	--	--
d) State Govt (s)	--	--	--	--	--	--	--	--	--
e) Venture Capital Funds	--	--	--	--	--	--	--	--	--
f) Insurance	--	--	--	--	--	--	--	--	--

ARUNJYOTI BIO VENTURES LIMITED

Companies									
g) Flls	--	--	--	--	--	--	--	--	--
h) Foreign Venture Capital Fund	--	--	--	--	--	--	--	--	--
i) Others	--	--	--	--	--	--	--	--	--
Sub Total (B) (1)	--	--	--	--	-	--	-	-	-
2. Non Institutions									
a) Bodies Corporate									
i) Indian	68795	--	68795	3.32	52955	-	52955	2.56	(0.7 6)
ii) Overseas	--	--	--	--	--	--	--	--	--
b) Individuals									
i) Individual Shareholders holding nominal share capital up to Rs.1 Lakh	191289	77300	268589	12.97	180949	77600	258549	12.48	(0.4 9)
ii) Individual Shareholders holding nominal share capital in excess of Rs.1 Lakh	1474215	69800	1544015	74.56	1501105	69800	1570905	75.86	1.30
c) Others									
i) IEPF	-	-	-	-	-	-	-	-	-
ii) Clearing members	1010	--	1010	0.05	-	-	-	-	(0.0 5)
iii) Non-Resident Indian (NRI)	-	-	-	-	-	-	-	-	-
Sub Total (B) (2)	1735309	147100	1882409	90.90	1735009	14710 0	1882409	90.90	--
Total Public Shareholding (B) = (B)(1) + (B) (2)	1735309	147100	1882409	90.90	1735009	14710 0	1882409	90.90	--
C. SHARES HELD BY CUSTODIAN FOR GDRS & ADRS	--	--	--	--	--	--	--	--	--
GRAND TOTAL (A+B+C)	1923800	147100	2070900	100	1923800	14710 0	2070900	100	--

(ii) Shareholding of Promoters

Sl. No	Shareholder's Name	Shareholding at the beginning of the year (as on 01-04-2019)			Shareholding at the end of the year (as on 31-03-2020)			% change in shareholding during the year
		No. of Shares	% of Total Shares of the Company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of Total Shares of the Company	% of Shares Pledged / encumbered to total shares	
1	Mittapalli Ramarao	94441	4.56	-	94441	4.56	-	--
2	M Praveen Kumar	94050	4.54	-	94050	4.54	-	--

ARUNJYOTI BIO VENTURES LIMITED

(iii) Change in Promoters' Shareholding: NIL

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year	Cumulative Shareholding during the year

(iv) Shareholding Pattern of top ten Shareholders (Other than Directors, Promoters and Holders of GDRs and ADRS):

Sl. No	Name of Shareholder	Shareholding at the beginning of the year		Date	Increase/Decrease in share holding	Reason	Cumulative Shareholding during the year	
		No. of Shares	% of total Shares of the Company				No. of Shares	% of total Shares of the Company
1.	Raghu Ram Renduchintala	205954	9.95	-	-	-	205954	9.95
2.	P Leela Madhuri Devi	145984	7.05	-	-	-	145984	7.05
3.	Srinivas Yalamarthy	100000	4.83	-	-	-	100000	4.83
4.	Ramesh Babu Chedella	99750	4.82	-	-	-	99750	4.82
5.	Srinivas Ayyalasomayajula	99739	4.82	31.05.2019	10000	Sale	89739	4.33
				07.06.2019	18739	Sale	71000	3.43
				14.06.2019	6300	Sale	64700	3.12
				28.06.2019	6400	Sale	58300	2.82
6.	P. Srinivasa Rao	80315	3.88	-	-	-	80315	3.88
7.	Pabbathi Venkata Mohan Rao	75881	3.66	-	-	-	75881	3.66
8.	Nallapareddy Vanaja	69800	3.37	-	-	-	69800	3.37
9.	Srinivasa Rao Grandhisiri	69500	3.36	-	-	-	69500	3.36
10.	Varun Naidu	66364	3.2	10.05.2019	23490	Purchase	89854	4.34

ARUNJYOTI BIO VENTURES LIMITED

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.	Name of the Shareholder	Shareholding at the beginning of the year		Change in Shareholding during the year			Cumulative Shareholding during the year	
		No. of Shares	% of total Shares of the Company	Date	Increase /Decrease in shareholding	Reason	No. of Shares	% of total Shares of the Company
A	Directors							
1	Mrs. Vanaja Kumari Dokiparthi	-	-	-	-	-	-	-
2	Polsani venkata Rama Rao	-	-	-	-	-	-	-
3.	Mr. Pabbathi Praveen Kumar	103664	5.01	-	-	-	103664	5.01
4	M Aditya Vardhan Reddy	-	-	-	-	-	-	-
5	Raja Kumar Babulal	-	-	-	-	-	-	-
6	Chandrashekar Kondari							

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment:

Particulars	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	-	-	-	-
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	-	-	-	-
Change in Indebtedness during the financial year				
Addition	-	-	-	-
Reduction	-	-	-	-
Net Change	-	-	-	-
Indebtedness at the end of the financial year				
i) Principal Amount	-	-	-	-
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	-	-	-	-

ARUNJYOTI BIO VENTURES LIMITED

V. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

S.No	Particulars of Directors	Mr. Pabbathi Praveen Kumar	Mr. Rajakumar Babulal	Total Amount (Rs)
1.	Gross salary (a) Salary as per provisions contained in Section 17(1) of the Income-tax Act, 1961. (b) Value of perquisites u/s 17(2) Income-tax Act, 1961. (c) Profits in lieu of salary under Section 17(3) Income-tax Act, 1961.	950000	-	950000
2.	Stock Option	-	-	-
3.	Sweat Equity	-	-	-
4.	Commission	-	-	-
	as % of profit	-	-	-
	Others	-	-	-
5.	Others, please specify	-	-	-
	Total (A)	9,50,000	-	950000
	Ceiling as per the Act	60,00,000	-	-

B. Remuneration to other Directors:

SL No	Particulars of Remuneration	Name of Directors				Total Amount (Rs)
		Vanaja kumar Dokiparthi	M. Aditya vardhan reddy	Polsani venkata rama Rao		
1	Independent Directors					
	Fee for attending Board /Committee Meetings	-	-	-	-	-
	Commission	-	-	-	-	-
	Others	-	-	-	-	-
	Total (1)	-	-	-	-	-
2	Other Non-Executive Directors					
	Fee for attending Board/Committee Meetings	-	-	-	-	-
	Commission	-	-	-	-	-
	Others	-	-	-	-	-
	Total (2)	-	-	-	-	-
	Total (B) = (1+2)	-	-	-	-	-
	Total Managerial Remuneration	Nil	Nil	Nil	Nil	Nil
	Overall Ceiling as per the Act	NA	NA	NA	NA	NA

ARUNJYOTI BIO VENTURES LIMITED

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

Sl. No	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary (Romi Agarwal) resigned on 03.01.2020	CFO Pabbathi Praveen Kumar	Total (Rs)
1.	Gross salary (a) Salary as per provisions contained in Section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under Section 17(3) Income-tax Act, 1961	-	1,35,000	As mentioned above	1,35,000
2.	Stock Option	-	-	-	-
3.	Sweat Equity	-	-	-	-
4.	Commission - as % of profit - others, specify.....	-	-	-	-
5.	Others, please specify	-	-	-	-
	Total	-	1,35,000	-	1,35,000

VI. PENALTIES/PUNISHMENT/COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment /Compounding Fees imposed	Authority (RD /NCLT / COURT]	Appeal made, if any (give Details)
A. COMPANY					
Penalty	NIL				
Punishment					
Compounding					
B. DIRECTORS					
Penalty	NIL				
Punishment					
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty	NIL				
Punishment					
Compounding					

FORM MR-3

SECRETARIAL AUDIT REPORT

(Pursuant to section 204(1) of the Companies Act, 2013 and
Rule 9 of the Companies (Appointment and Remuneration of Managerial
Personnel) Rules, 2014

FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2020

To,

The Members

Arunjyoti Bio Ventures Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Arunjyoti Bio Ventures Limited (hereinafter called “the Company”). Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company’s Books, Papers, Minutes Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the financial year commencing from 1st April, 2019 and ended 31st March, 2020 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made herein after:

1. We have examined the books, papers, minutes books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st of March, 2020 according to the provisions of:
 - (i) The Companies Act, 2013 (the Act) and the rules made there under;
 - (ii) The Securities Contracts (Regulation) Act, 1956 (‘SCRA’) and the Rules made there under;
 - (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;

ARUNJYOTI BIO VENTURES LIMITED

- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment (FDI), Overseas Direct Investment and External Commercial Borrowings;
2. Compliance status in respect of the provisions of the following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI ACT') is furnished hereunder for the financial year 2019-20:-
- i. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; **Complied with yearly and event based disclosures, wherever applicable.**
 - ii. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Amended Regulations 2018; **The Company has framed code of conduct for regulating & reporting trading by insiders and for fair disclosure and displayed the same on the Company's website i.e. www.orbisagri.com**
 - iii. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **Not Applicable as the company has not issued any shares during the year under review.**
 - iv. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; **Not Applicable as the Company has not issued any Employee Stock Options during the year under review.**
 - v. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; **Not Applicable as the Company has not issued any debt securities during the year under review.**
 - vi. The Securities and Exchange Board of India (Registrars to an issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the year under review. However, the company has Venture Capital and Corporate Investments Private Limited as its Share Transfer Agent.**
 - vii. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; **Not Applicable as the company has not delisted/ proposed to delist its equity shares during the year under review.**
 - viii. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **Not Applicable as the Company has not bought back/ proposed to buy-back any of its securities during the year under review.**

ARUNJYOTI BIO VENTURES LIMITED

- a. The Water (Prevention & Control of Pollution) Act, 1974, Read with Water (Prevention & Control of Pollution) Rules, 1975.
- b. The Air (Prevention and Control of Pollution) Act, 1981.
- c. The Water (Prevention & Control of Pollution) Act, 1974, Read with Water (Prevention & Control of Pollution) Rules, 1975.
- d. Hazardous Wastes (Management, Handling and Transboundary Movement) Rules, 2008.
- e. The Insecticides Act, 1968 and rules made thereunder.
- f. Fertilizer Control (Order)
- g. The Payment of Gratuity Act, 1972
- h. Employees Provident Fund and Miscellaneous Provisions Act, 1952
- i. Employees State Insurance Act, 1948

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 were complied with to the extent applicable.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above including the following:

- a) During the year the Company has conducted 5 meetings of the Board of Directors, 4 meetings of the Audit committee, 1 Meetings of Stakeholder Relationship Committee, 2 meetings of Nomination and Remuneration Committee and 1 meeting of Independent Directors. We have also examined compliance with the applicable clauses of the Secretarial Standards issued by the Institute of Company secretaries of India.
- b) As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we report that

ARUNJYOTI BIO VENTURES LIMITED

- (i) the provisions of the Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of:
- External Commercial Borrowings were not attracted to the Company under the financial year under report;
 - Foreign Direct Investment (FDI) was not attracted to the company under the financial year under report;
 - Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad was not attracted to the company under the financial year under report.
- (ii) As per the information and explanations provided by the company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we report that the Company has not made any GDRs/ADRs or any Commercial Instrument under the financial year under report.

We further report that:

- The Company has a CFO Mr. Pabbathi Praveen Kumar. Mr.RomiAgarwalresigned as Company Secretary and compliance officer on 03.01.2020.
- The Company has not appointed internal auditors.
- The website of the Company contains policies as specified by SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and the provisions of Companies Act, 2013.
- The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
- Adequate notice of board meeting is given to all the directors along with agenda at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and meaningful participation at the meeting.
- As per the minutes of the meeting duly recorded and signed by the Chairman, the decisions of the Board were unanimous and no dissenting views have been recorded.

ARUNJYOTI BIO VENTURES LIMITED

- We, further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
- The Compliance by the Company of applicable financial laws like Direct and Indirect Tax laws has not been reviewed thoroughly in this audit since the same has been subject to review by statutory financial audit and other designated professionals.
- We further report that during the year under report, the Company has not undertaken event/action having a major bearing on the company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards etc.

For Vivek Surana & Associates

Sd/-

Vivek Surana

Proprietor

C.P. No: 12901, M. No.: A24531

UDIN: A024531B000517034

Place: Hyderabad

Date: 28.07.2020

ARUNJYOTI BIO VENTURES LIMITED

Annexure A

To

The Members of

Arunjyoti Bio Ventures Limited

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial Audit report is neither an assurance as to future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For Vivek Surana & Associates

Sd/-

Vivek Surana
Proprietor

Place: Hyderabad

Date: 28.07.2020

C.P. No: 12901, M. No.: A24531

UDIN: A024531B000517034

ARUNJYOTI BIO VENTURES LIMITED

CERTIFICATE BY THE WHOLE-TIME DIRECTOR AND CFO OF THE COMPANY

To

The Board of Directors

Arunjyoti Bio Ventures Limited

Dear Sirs,

As required under Regulation 17(8) read with Part B, Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we state that:

1. We have reviewed the financial statements and the cash flow statement for the year ended 31st March 2020 and to the best of our knowledge and belief;
 - a. These statements do not contain any materially untrue statement nor omit any material fact nor contain statements that might be misleading, and
 - b. These statements present a true and fair view of the company's affairs and are in compliance with the existing accounting standards, applicable laws and regulations.
2. There are, to the best of my knowledge and belief, no transactions entered into by the company during the year, which are fraudulent, illegal or violative of the company's code of conduct.
3. We accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the company and I have disclosed to the auditors and the audit committee, deficiencies in the design or the operation of internal controls, if any, of which I was aware and the steps that I have taken or propose to take and rectify the identified deficiencies and,
4. That we have informed the auditors and the audit committee of:
 - a) Significant changes in the internal control during the year;
 - b) Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - c) Instances of significant fraud of which we have become aware and the involvement of any employee having a significant role in the company's internal control system.

For and on behalf of the Board
Arunjyoti Bio Ventures Limited

Place: Hyderabad
Date: 28.07.2020

Rajkumar Babulal
Whole-time Director

Pabbathi Praveen Kumar
Whole-time Director cum CFO

ARUNJYOTI BIO VENTURES LIMITED

DISCLOSURE WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT

As per Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company hereby discloses the details of unpaid/unclaimed dividend and the respective share thereof as follows:

Aggregate No. of Shareholders and the outstanding shares in the suspense account at the beginning of the year.	No. of shareholders who approached the company for transfer of shares from suspense account during the year.	No. of shareholders to whom shares were transferred from suspense account during the year.	Aggregate No. of Shareholders and the outstanding shares in the suspense account at the end of the year.
NIL	NIL	NIL	NIL

*** Voting Right on these shares shall remain frozen till the rightful owner of such shares claims the shares.*

Note: The Company has never declared dividends since its inception and therefore there is no amount lying in unpaid/unclaimed dividend account.

ANNEXURE -III

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Industry structure, developments and performance

Agriculture is the third largest sector of Indian Economy, which contributes around 17% of total GDP of the Country. Fertilizer Industry, with the emerging scenario, plays vital role in the growth of Agriculture Sector. The balanced use of chemical fertilizer is important not only for increasing agricultural productivity but also for sustaining soil fertility. Single Super Phosphate is a multi-nutrient fertilizer containing phosphate (16%) and sulphur (11%) as primary nutrients. SSP is applied as a basal fertilizer being rich in secondary nutrients like calcium and magnesium oxide and several micro nutrients. It is an essential Fertilizer for crops likes Oilseeds, Pulses, Sugarcane, Fruits and Vegetables, Tea etc. and for sulphur deficient soils.

Fertilizer industry in India operates in public, private and co-operative sector, with the private sector occupying a larger share in the manufacturing capacity. Fertilizers sector being highly energy & capital intensive, cost of fertilizers is unavoidably high. In order to ensure availability of fertilizers to the majority of the small & marginal farmers at affordable prices, this sector is highly regulated and controlled by Gol for pricing and distribution of fertilizers. At present, Urea prices are highly subsidized and administered under New Urea policy-2015 whereas P & K Fertilizers are partially decontrolled and subsidy is disbursed based on the nutrient content available in the particular fertilizer under Nutrient Based Subsidy introduced by Gol w.e.f. 01-04-2010.

OPPORTUNITIES:

The volume growth during FY19-20 has been driven by good opening inventory levels compared with the previous and low base effect and was supported by moderate growth in the domestic production of urea and higher import for non-urea fertilizers.

THREATS

Many challenges being faced by Fertilizer Industry which need to be addressed including delay in payment of subsidy due to inadequate subsidy budget of the Gol for Fertilizers, over regulations and procedural delays, unviable investment by Industry on energy saving schemes to meet the stiff energy norms fixed under New Urea Policy (NUP-2015) without any dispensation from Gol, Implementation of DBT which has further aggravated the problem of working capital due to change of subsidy payment from supply to sale. Lack of availability of domestic gas, increasing trend in the price of RLNG and lower price of Urea in international market is also adversely

ARUNJYOTI BIO VENTURES LIMITED

impacting the profitability of the Urea manufactures. The fertilizer industry is highly vulnerable to the adverse climatic conditions which badly impact, the fertilizer industry.

Segment-wise or product-wise performance:

Your Company has shown good results during the year under review and achieved sales and other income of Rs. 731.17 lakhs and net profit of Rs. 10.57 Lakhs as compared to sales and other income of Rs. 371.90 lakhs and net profit of Rs. 4.38 lakhs achieved in the previous financial year.

The Company does not have any geographical segment.

Outlook:

GOI has approved the New Urea Policy effective over next four financial years. The policy has multiple objectives of maximizing indigenous production of Urea and promoting energy efficiency. In order to enhance the use efficiency of Urea, Government had also mandated to produce 75% of domestic Urea as neem coated, so that farmers are benefited.

Risks and concerns:

The growth trajectory of the Indian fertilizer industry has camouflaged the impending challenges with which it is faced. Adverse Agro climatic conditions can impact the performance of the company. Scanty rains because of monsoon failures which affect the industry. Fertilizer marketing is undergoing a sea change in the emerging scenario in the view of entry of new players and competitors.

Internal control systems and their adequacy:

The company's internal control/supervisory system is established to ensure that the board and management are able to achieve their business objectives in a prudent manner, safeguarding the interest of company's shareholders and other stakeholders whilst minimizing the key risk such as fraud, misleading financial statements, breach of legal and contractual obligations, unauthorized business activities.

Discussion on financial performance with respect to operational performance:

Financial and operational performance forms part of the Annual Report and is presented elsewhere in the report.

ARUNJYOTI BIO VENTURES LIMITED

Material developments in Human Resources / Industrial Relations front, including number of people employed.

There are no material developments in the Human Resources area. The Industrial relations have been considered to be satisfactory. The Company constantly reviews the manpower requirements and effective steps are being taken to meet the requirements.

Your company follows a strategy of attracting and retaining the best talent and keep employees engaged, motivated and innovative. The company continues to have cordial relations with its employees and provide personnel development opportunities for all round exposure to them.

Details of any change in return on net worth as compared to the immediately previous financial year along with a detailed explanation thereof: There is change on return on net worth as compared to the immediately previous financial year.

Disclosure of Accounting Treatment:

The Company has complied all the requirement of Accounting standard applicable to the Company and during the year company has not changed any accounting policies.

NOTE

Readers are advised to kindly note that the above discussion contains statements about risks, concerns, opportunities, etc., which are valid only at the time of making the statements. A variety of factors known/unknown expected or otherwise may influence the financial results. We do not expect these statements to be updated or revised to take care of any changes in the underlying presumptions.

Readers may therefore appreciate the context in which these statements are made before making use of the same.

ARUNJYOTI BIO VENTURES LIMITED

ANNEXURE-IV

The details of remuneration during the year 2019-2020 as per Rule 5 (1) of the Companies (Appointment & Remuneration of Managerial Personnel) Rules 2015 are as follows:

Sl. No	Disclosure Requirement	Disclosure Details	
i.	Ratio of the Remuneration of each Director to the median Remuneration of the employees of the Company for the Financial year	The ratio of remuneration of Mr. P. Pabbathi Praveen Kumar to the median remuneration of the employees is 4.87:1	
ii.	Percentage increase in the remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year	Directors, Chief Executive Officer, Chief Financial Officer and Company Secretary	% increase in remuneration in the financial year
		P. Pabbathi Praveen Kumar	--

iii. Percentage increase in the median remuneration of employees in the financial year 2019-20: NIL

iv. Number of permanent employees on the rolls of the Company as on 31st March, 2020: 10.

v. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:

The average annual increase in salaries of employees was NIL

Increase in the managerial remuneration for the year was NIL.

Vi. Affirmation that the remuneration is per the remuneration policy of the Company:

The Company is in compliance with its remuneration policy.

ARUNJYOTI BIO VENTURES LIMITED

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis: NIL
 - (a) Name(s) of the related party and nature of relationship
 - (b) Nature of contracts/arrangements/transactions
 - (c) Duration of the contracts / arrangements/transactions
 - (d) Salient terms of the contracts or arrangements or transactions including the value, if any
 - (e) Justification for entering into such contracts or arrangements or transactions
 - (f) Date(s) of approval by the Board
 - (g) Amount paid as advances, if any:
 - (h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188
2. Details of material contracts or arrangement or transactions at arm's length basis: Nil
 - (a) Name(s) of the related party and nature of relationship
 - (b) Nature of contracts/arrangements/transactions
 - (c) Duration of the contracts / arrangements/transactions
 - (d) Salient terms of the contracts or arrangements or transactions including the value, if any:
 - (e) Date(s) of approval by the Board, if any:
 - (f) Amount paid as advances, if any:

ARUNJYOTI BIO VENTURES LIMITED

Independent Auditors' Report

To

The Members,

ARUNJYOTHI BIO VENTURES LIMITED

Report on the IndAS financial statements

We have audited the accompanying Ind AS financial statements of M/S ARUNJYOTHI BIO VENTURES LIMITED (“the Company”), which comprise the Balance Sheet as at 31st March, 2020, the Statement of Profit and Loss (Including other comprehensive income), the Statement of cash flows and the Statement of Changes in Equity for the year then ended, and a summary of the significant accounting policies and other explanatory information (herein referred to as ‘Ind AS financial statements’).

Management’s Responsibility for the Financial Statements

The Company’s Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 (“the Act”) with respect to the preparation of these Ind AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in Equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under Section 133 of the Act, read with relevant rules issued there under. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

ARUNJYOTI BIO VENTURES LIMITED

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Ind AS financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Ind AS financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the Ind AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the Ind AS financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Ind AS financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including the Ind AS, of the financial position of the Company as at 31st March, 2020, and its financial performance including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of section 143(11) of the Act, we give in the Annexure –A a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. **As required by Section 143 (3) of the Act, we report that:**
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

ARUNJYOTI BIO VENTURES LIMITED

- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss, the statement of Cash flows and the changes in Equity dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid Ind AS financial statements comply with the Accounting Standards specified under Section 133 of the Act, relevant rules issued there under.
- (e) On the basis of the written representations received from the directors as on 31st March, 2020 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2020 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) with respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B"; and
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For M M REDDY & CO.,
Chartered Accountants
Firm Reg No. 010371S
UDIN: 20213077AAAAHM4139

M Madhusudhana Reddy
Partner
Membership No. 213077

Place: Hyderabad
Date : 28.07.2020

ARUNJYOTI BIO VENTURES LIMITED

Annexure – A to the Independent Auditors' Report:

The Annexure referred to the Independent auditors' report to the members of the company on the Ind AS financial statements for the year ended 31 March 2020, we report that

- i. (a) The Company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.
- (b) A major portion of fixed assets have been physically verified by the management during the year at reasonable intervals; no material discrepancies were noticed on such verification.

The books of accounts of the company does not carry any inventory for the reporting year. Hence the above point as per CARO, 2016 is NOT APPLICABLE.

- (c) According to the information and explanations given to us, the company does not have any immovable property hence paragraph 3 (i)(c) of the Companies (Auditor's Report) Order, 2016 is not applicable.
- ii. The inventory has been physically verified by the management during the year at reasonable intervals; no material discrepancies were noticed on such verification and have been properly dealt with in the books of account.
- iii. The Company has Not granted any loans, secured or unsecured to companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013.
- iv. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the Act, with respect to the loans and investments made.
- v. The Company has not accepted any deposits within the meaning of Sections 73 to 76 or any other relevant provisions of the Companies Act, 2013 and no order has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any tribunal.
- vi. In our opinion and according to the information and explanations given to us, maintenance of cost records as specified by the Central Government under sub section (1) of section 148 of the Companies Act, 2013 is not applicable to the company.

ARUNJYOTI BIO VENTURES LIMITED

- vii. (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company is regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income-tax, Goods and Service Tax, Customs Duty, cess and any other statutory dues to the appropriate authorities and no undisputed amounts payable were outstanding as at 31st March, 2020 for a period of more than six months from the date they became payable.
- (b) According to the information and explanations given to us and the records of the company examined by us, there are no dues of Income Tax or Goods and Service Tax or Customs Duty as at 31st March, 2020 which have not been deposited on account of a dispute.
- viii. The Company does not have any loans or borrowings from any financial institution, banks, government or debenture holders during the year. Accordingly, paragraph 3 (viii) of the Companies (Auditor's Report) Order, 2016 is not applicable.
- ix. The Company has not raised any money by way of initial public offer or further public offer (including debt instruments) and term loans during the year. Accordingly, paragraph 3 (ix) of the Companies (Auditor's Report) Order, 2016 is not applicable.
- x. According to the information and explanations given to us, no fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
- xi. The company has not paid or provided any managerial remuneration during the year. Accordingly, paragraph 3 (xi) of the Companies (Auditor's Report) Order, 2016 is not applicable.
- xii. In our opinion and according to the information and explanations given to us, the Company is not a nidhi company. Accordingly, paragraph 3(xii) of the Companies (Auditor's Report) Order, 2016 is not applicable.
- xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- xiv. According to the information and explanations give to us and based on our examination of the records of the Company, the Company has not

ARUNJYOTI BIO VENTURES LIMITED

made any preferential allotment of equity share converted in to equal number equity shares of the company. The requirement of Section 42 and all the other applicable provisions of the Companies Act, 2013 and SEBI Regulations were complied with.

- xv. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the Companies (Auditor's Report) Order, 2016 is not applicable.
- xvi. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

For M M REDDY & CO.,
Chartered Accountants
Firm Reg No. 010371S
UDIN: 20213077AAAAHM4139

M Madhusudhana Reddy
Partner
Membership No. 213077

Place: Hyderabad
Date : 28.07.2020

ARUNJYOTI BIO VENTURES LIMITED

Annexure - B to the Independent Auditors' Report:

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of M/S **ARUNJYOTI BIO VENTURES LIMITED** ("the Company") as of 31st March 2020 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to

ARUNJYOTI BIO VENTURES LIMITED

provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For M M REDDY & CO.,
Chartered Accountants
Firm Reg No. 010371S
UDIN: 20213077AAAAHM4139

M Madhusudhana Reddy
Partner
Membership No. 213077

Place: Hyderabad
Date : 28.07.2020

ARUNJYOTI BIO VENTURES LIMITED

Statement of Financial Position as at March 31, 2020

(Amt. in Rs.)

	Particulars	Note No.	As at Mar 31, 2020	As at March 31, 2019
I	ASSETS			
1	Non-current assets			
	(a) Property, plant and equipment	1	-	-
	(b) Right to use assets		-	-
	(c) Capital work in progress		-	-
	(d) Investment properties		-	-
	(e) Good will		-	-
	(f) Other intangible Assets		-	-
	(g) Intangible Assets under Development		-	-
	(h) Biological Assets other than Bearer Plants		-	-
	(d) Financial assets		-	-
	(i) Investments	2	-	-
	(ii) Trade receivables	3	-	-
	(iii) Loans	4	1,49,71,192	1,49,71,192
	(vi) other Financial assets	5	-	-
	(e) Deferred Tax Asset (Net)	6	-	-
	(f) Other non-current asset	7	-	-
	Total non-current assets (A)		1,49,71,192	1,49,71,192
2	Current assets			
	(a) Inventories	8	2,96,484	52,89,553
	(a) Financial assets			
	(i) Investments	2	-	-
	(ii) Trade receivables	3	2,67,25,481	2,35,59,851
	(iii) Cash and cash equivalents	9	1,11,76,399	34,58,225
	(iv) Bank Balances other than (iii) above		-	-
	(v) other financial assets	5	-	-
	(b) Current Tax Asset (Net)	6	-	-
	(c) Other current assets	10	58,24,519	75,59,658
	Total current assets (B)		4,40,22,882	3,98,67,287
	Non Current Assets Classified as Held for Sale (C)	10.1	-	-
	Total assets (A+B+C)		5,89,94,074	5,48,38,479
II	EQUITY AND LIABILITIES			
1	Equity			
	(a) Equity share capital	11	2,07,09,000	2,07,09,000
	(b) Other equity	11.1	(19,79,487)	(30,00,205)
	Total equity (A)		1,87,29,513	1,77,08,795
2	Liabilities			
(i)	Non-current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	12	-	-
	(ii) Trade Payables	13	-	-
	(iii) Other Financial Liabilities	14	-	-
	(b) Long term provisions	15	-	-
	(c) Deferred tax Liabilities(Net)	6	-	-
	(d) Other non Current Liabilities		-	-
	Total non-current liabilities (B)		-	-
(ii)	Current liabilities			
	(a) Financial liabilities			
	(i) Borrowings	12	-	-
	(ii) Trade payables	13	2,18,42,239	2,10,57,322
	(iii) Other financial liabilities	14	-	-
	(b) Short term provisions	15	2,88,319	84,319
	(c) Other current liabilities	16	1,81,34,003	1,59,88,043
	(d) Current Tax Liabilities (net)	6	-	-
	Total current liabilities (C)		4,02,64,561	3,71,29,684
	Total liabilities (D=B+C)		4,02,64,561	3,71,29,684
	Total equity and liabilities (A+D)		5,89,94,074	5,48,38,479

The notes are an integral part of the financial statements

As per our Report of even date
For M M REDDY & CO.,
Chartered Accountants
Firm Reg No:010371S

For and on behalf of the Board of Directors
Arunjyoti Bio Ventures Limited

CA. M. Madhusudhana Reddy
Partner
Membership No: 213077
UDIN: 20213077AAAAHM4139

Sd/-
Pabbathi Praveen Kumar
Wholetime Director cum CFO
DIN:02009879

Sd/-
Babulal Raja Kumar
Wholetime Director
DIN:07529064

Place: Hyderabad
Date : 28/07/2020

ARUNJYOTI BIO VENTURES LIMITED

Statement of Profit and Loss and Other Comprehensive Income for the Year ended Mar 31, 2020

(Amt. in Rs.)

	Note No.	For the year ended March 31, 2020	For the year ended March 31, 2019
Continuing Operations			
I Revenue from operations	17	7,30,88,613	3,71,74,710
II Other income	18	28,293	15,627
III Net gain on de-recognition of financial assets at amortised cost	19	-	-
IV Net gain on reclassification of financial assets	20	-	-
V Total income		7,31,16,906	3,71,90,337
VI Expenses			
(a) Cost of material Consumed	21	6,08,97,004	3,14,23,627
(b) Purchase of Stock in Trade		-	-
(c) Changes in stock of finished goods, work-in progress and stock-in-trade	22	-	-
(d) Employee benefits	23	31,34,506	43,00,133
(e) Finance cost	24	1,929	1,431
(f) Depreciation expense	25	-	-
(g) Impairment expenses/losses		-	-
(h) Net loss on de-recognition of financial assets at amortized cost	19	-	-
(i) Net loss on reclassification of financial assets	20	-	-
(c) Other expenses	26	77,74,431	10,26,898
Total expenses (VI)		7,18,07,870	3,67,52,089
VII Profit/(loss) before Share of profit/(loss) of associates / joint ventures, exceptional items and tax (V - VI)		13,09,036	4,38,248
VIII Share of profit/(loss) of associates			
Share of profit/(loss) of joint ventures			
IX Profit/(Loss) before exceptional items and tax		13,09,036	4,38,248
X Exceptional itmes			
XI Profit before Tax		13,09,036	4,38,248
XII Tax expense :			
a. Current tax		2,95,920	84,319
b. Deferred tax		(7,602)	(84,319)
XIII Profit/(loss) for the year from continuing operations (XI-XII)		10,20,718	4,38,248
Discontinued Operations			
XIV Profit/(loss) from discontinued operations		-	-
XV Tax Expense of discontinued operations		-	-
XVI Profit/(loss) from discontinued operations (XIV +XV)		-	-
XVII Profit/(loss) for the year (XIII+XVI)		10,20,718	4,38,248
XIX Other comprehensive income(OCI)			
A (i) Items that will not be recycled to profit or loss			
B (i) Items that may be reclassified to profit or loss		-	-
Total other comprehensive income		-	-
IX. Total comprehensive income for the year (V+ VI)		10,20,718	4,38,248
X. Earning per equity share (for Continuing Operations)			
(i) Basic		0.49	0.21
(ii) Diluted.		0.49	0.21
XI. Earnings per equity share (for discontinued operation):			
(i) Basic		-	-
(ii) Diluted.		-	-
XII. Earnings per equity share(for Continued and discontinued operation):			
(i) Basic		0.49	0.21
(ii) Diluted.		0.49	0.21

The notes are an integral part of the financial statements

As per our Report of even date
For M M REDDY & CO.,
Chartered Accountants
Firm Reg No:010371S

For and on behalf of the Board of Directors
Arunjyoti Bio Ventures Limited

CA. M. Madhusudhana Reddy
Partner
Membership No: 213077
UDIN: 20213077AAAAM4139

Sd/-
Pabbathi Praveen Kumar
Wholetime Director cum CFO
DIN:02009879

Sd/-
Babulal Raja Kumar
Wholetime Director
DIN:07529064

Place: Hyderabad
Date : 28/07/2020

ARUNJYOTI BIO VENTURES LIMITED

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 31st March, 2020

(Amt. in Rs.)

		As at Mar 31, 2020	As at March 31, 2019
A	CASH FROM OPERATING ACTIVITIES		
	(Loss)/Profit before tax and extraordinary items	13,09,036	4,38,248
	Adjustment for:		
	Income tax expense recognised in profit or loss	-	-
	Finance costs recognised in profit or loss	-	-
	Investment income recognised in profit or loss	-	-
	Gain on disposal of property, plant and equipment	-	-
	Gain on disposal of a subsidiary	-	-
	Gain on disposal of interest in former associate	-	-
	Net (gain)/loss recorded in profit or loss on financial liabilities designated as at fair value through profit or loss	-	-
	Net (gain)/loss arising on financial assets mandatorily measured at fair value through profit or loss	-	-
	Net loss/(gain) arising held for trading financial liabilities	-	-
	Hedge ineffectiveness on cash flow hedges	-	-
	Net (gain)/loss on disposal of available-for-sale financial assets	-	-
	Impairment loss recognised on trade receivables	-	-
	Reversal of impairment loss on trade receivables	-	-
	Depreciation and amortisation of non-current assets	-	-
	Impairment of non-current assets	-	-
	Net foreign exchange (gain)/loss	-	-
	Expense recognised in respect of equity-settled share-based payments	-	-
	Expense recognised in respect of shares issued in exchange for goods/services	-	-
	Amortisation of financial guarantee contracts	-	-
	Operating Profit before Working Capital Changes	13,09,036	4,38,248
	Movement for Working Capital:		
	Increase in trade and other receivables	(31,65,630)	2,15,72,421
	(Increase)/decrease in amounts due from customers under construction contracts	-	-
	(Increase)/decrease in inventories	49,93,069	(52,89,553)
	(Increase)/decrease in other assets	17,80,849	(54,217)
	Decrease in trade and other payables	7,84,918	(4,90,76,170)
	Increase/(decrease) in amounts due to customers under construction contracts	-	-
	Increase/(decrease) in provisions	(1,18,201.00)	2,04,000
	(Decrease)/increase in deferred revenue	-	-
	(Decrease)/increase in other liabilities	21,45,959	26,74,176
	Changes in non current assets and liabilities		
	Decrease/(Increase) in loans & advances	-	27,85,122
	Decrease/(Increase) in Long Term Provisions	-	-
	Decrease/(Increase) in Other non Current Assets	-	-
	Cash generated from operations	80,52,201	(2,70,68,174)
	- Income taxes paid	(3,34,028)	-
	Net Cash flow before extraordinary items	77,18,173	(2,70,68,174)
	- Extraordinary & Prior period items	-	-
	NET CASH FROM OPERATING ACTIVITIES	77,18,173	(2,70,68,174)

ARUNJYOTI BIO VENTURES LIMITED

B	CASH FLOW FROM INVESTING ACTIVITIES: Payments to acquire financial assets - Proceeds on sale of financial assets - Interest received - Royalties and other investment income received - Dividends received from associates - Other dividends received - Amounts advanced to related parties - Repayments by related parties - Payments for property, plant and equipment - Proceeds from disposal of property, plant and equipment - Payments for investment property - Proceeds from disposal of investment property - Payments for intangible assets - Net cash outflow on acquisition of subsidiaries - Net cash inflow on disposal of subsidiary - Net cash inflow on disposal of associate -		-
	NET CASH FROM INVESTING ACTIVITIES		-
C	CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity instruments of the Company - Proceeds from issue of convertible notes - Payment for share issue costs - Payment for buy-back of shares - Payment for share buy-back costs - Proceeds from issue of redeemable preference shares - Proceeds from issue of perpetual notes - Payment for debt issue costs Proceeds from borrowings - Proceeds from borrowings - (19,34,999) Proceeds from government loans - Proceeds on disposal of partial interest in a subsidiary that does not involve loss of control - Dividends paid on redeemable cumulative preference - Dividends paid to owners of the Company - Interest paid - Long Term Provisions -		-
	NET CASH FROM FINANCING ACTIVITIES		(19,34,999)
	NET INCREASE IN CASH & CASH EQUIVALENTS		77,18,173
	Cash and cash equivalents at the beginning of the year 1.04.2019		3,24,61,398
	Effects of exchange rate changes on the balance of cash held in foreign currencies -		-
	Cash and cash equivalents at the end of the year as on 31.03.2020		1,11,76,398
Reconciliation of cash and cash equivalents as per the cash flow Statement			
	Cash and cash equivalents (Note-9.1)		34,58,225
	Bank overdraft		1,11,76,399
	Balance as per statement of cash flows		1,11,76,399
The notes are an integral part of the financial statements			

As per our Report of even date
 For M M REDDY & CO.,
 Chartered Accountants
 Firm Reg No:010371S

CA. M. Madhusudhana Reddy
 Partner
 Membership No: 213077
 UDIN: 20213077AAAAHM4139

Place: Hyderabad
 Date : 28/07/2020

For and on behalf of the Board of Directors
 Arunjyoti Bio Ventures Limited

Sd/-
 Pabbathi Praveen Kumar
 Wholetime Director cum CFO
 DIN:02009879

Sd/-
 Babulal Raja Kumar
 Wholetime Director
 DIN:07529064

ARUNJYOTI BIO VENTURES LIMITED

Statement of Changes in Equity For the year ended 31 March 2020

Equity share capital

	(Amount in Rs.)
	Amount
Balance as at the 1 April 2018	-
Changes in equity share capital during 2018-19	-
Balance as at the 31 March 2019	-
Changes in equity share capital during 2019-20	-
Balance as at the 31 March 2020	-

Other equity

Particulars	Reserves and surplus			Items of Other comprehensive income (OCI)	Total
	Capital Reserve	Securities Premium	Retained earnings	Others	
				Others	
Balance at 1 April 2018	-	-	-	-	-
Total comprehensive income for the year ended 31 March 2019	-	-	-	-	-
Profit or loss	-	-	4,38,248	-	4,38,248
Other comprehensive income(net of tax)	-	-	-	-	-
Total comprehensive income	-	-	4,38,248	-	4,38,248
Transactions with owners in their capacity as owners directly in equity	-	-	-	-	-
Balance at 31 March 2019	-	-	4,38,248	-	4,38,248
Total comprehensive income for the year ended 31 March 2020	-	-	-	-	-
Profit or loss	-	-	10,20,718	-	10,20,718
Other comprehensive income(net of tax)	-	-	-	-	-
Total comprehensive income	-	-	10,20,718	-	10,20,718
Transactions with owners in their capacity as owners	-	-	-	-	-
Balance at 31 March 2020	-	-	14,58,966	-	14,58,966

As per our Report of even date
For M.M. REDDY & CO.,
Chartered Accountants
Firm Reg No:010371S

CA. M. Madhusudhana Reddy
Partner
Membership No: 213077
UDIN: 20213077AAAAHM4139

Place: Hyderabad
Date : 28/07/2020

For and on behalf of the Board of Directors
Arunjyoti Bio Ventures Limited

Sd/-
Pabbathi Praveen Kumar
Wholtime Director cum CFO
DIN:02009879

Sd/-
Babulal Raja Kumar
Wholtime Director
DIN:07529064

ARUNJYOTI BIO VENTURES LIMITED

Notes to accounts

Corporate Information:

ARUNJYOTI BIO VENTURES LIMITED (“the Company”) was incorporated in India in the year 1986 having its Registered office at PLOT NO. 45, P & T COLONY, KARKHANA, SECUNDERABAD, HYDERABAD, TG 500009 IN.

Disclosure of Significant Accounting Policies:

1. Basis for Preparation of Financial Statements:

a) Compliance with Indian Accounting Standards (Ind AS)

The Ind AS financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 notified under section 133 of the Companies Act, 2013.

The Ind AS financial statements have been prepared on the historical cost on Non-Going Concern basis except for certain instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Accordingly, the Company has prepared these Financial Statements which comprise the Balance Sheet as at 31 March, 2020, the Statement of Profit and Loss for the year ended 31 March 2020, the Statement of Cash Flows, Statement of Changes in Equity for the year ended 31 March 2020 and accounting policies and other explanatory information (together hereinafter referred to as ‘Ind AS Financial Statements’ or ‘financial statements’).

These financial statements are approved by the Board of Directors on 28.07.2020.

b) Basis of Preparation of financial statements

The separate financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) under historical cost convention on accrual basis as per the provisions of Companies Act 2013.

- Financial instruments – measured at fair value;
- Assets held for sale – measure at fair value less cost of sale;

ARUNJYOTI BIO VENTURES LIMITED

- Plan assets under defined benefit plans—measure daft air value
- Employee share-based payments—measure daft air value
- Biological assets—measure daft air value
- In addition, the carrying values of recognized assets and liabilities, designated as hedged items in fair value hedges that would otherwise be carried at cost, are adjusted to record changes in the fair values attributable to the risks that are being hedged in effective hedge relationship.

Current and Non-Current Classification:

The Company presents assets and liabilities in the balance sheet based on current / non-current classification. An asset is classified as current when it satisfies any of the following criteria: it is expected to be realized in, or is intended for sale or consumption in, the Company's normal operating cycle. it is held primarily for the purpose of being traded;

- It is expected to be realized within 12 months after the reporting date; or
- It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.
- All other assets are classified as non-current.
- A liability is classified as current when it satisfies any of the following criteria:
 - It is expected to be settled in the Company's normal operating cycle;
 - It is held primarily for the purpose of being traded
 - It is due to be settled within 12 months after the reporting date; or the Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification
- All other liabilities are classified as non-current

c) Use of estimates and judgment

The preparation of the financial statements in conformity with Ind AS, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

ARUNJYOTI BIO VENTURES LIMITED

This note provides an overview of the areas where there is a higher degree of judgment or complexity. Detailed information about each of these estimates and judgments is included in relevant notes together with information about the basis of calculation.

The areas involving critical estimates or judgments are:

S. no	Name of the estimate	Note No	Remarks
1	Goodwill impairment	Not applicable	No amount provided during the current Financial year
2	Useful life of intangible asset	Not Applicable	No intangible assets held by the company for the current financial year
3	Measurement of contingent liabilities and contingent purchase consideration in a business combination	Not applicable	Contingent transactions are recognized based on happening contingent event. No contingent liabilities for the report
4	Current tax expense and current tax payable	Note No.6	As per the Ind AS.12
5	Deferred tax assets for carried forward tax losses	Note No.6	As per the Ind AS.12

d. Standards issued but not effective (based on Exposure drafts available as on date)

The amendments are proposed to be effective for reporting periods beginning on or after 1 April 2020.

i). Issue of Ind AS117–Insurance Contracts:

Ind AS 117 supersedes Ind AS 104 Insurance contracts. It establishes the principles for the recognition, measurement, presentation and disclosure of insurance contracts within the scope of the standard. Under the Ind AS 117 model, insurance contract liabilities will be calculated as the present value of future insurance cash flows with a provision for risk.

Application of this standard is not expected to have any significant impact on the Company's financial statements.

ARUNJYOTI BIO VENTURES LIMITED

Amendments to existing Standards

Ministry of Corporate Affairs has carried out amendments of the following accounting standards:

1. IndAS 103 – Business Combination - nil
2. Ind AS 1, Presentation of Financial Statements and Ind AS 8, Accounting Policies, Changes in Accounting Estimates and Errors
3. IndAS 40 – Investment Property - nil

The Company is in the process of evaluating the impact of the new amendments issued but not yet effective.

2. Significant accounting policies:

A summary of the significant accounting policies applied in the preparation of the financial statements is as given below. These accounting policies have been applied consistently to all the periods presented in the financial statements.

2.1 Ind AS 105: Non-Current Assets held for Sale or Discontinued Operations

S. No	Particulars of Disclosures	As at 31 st March 2020 (Rs.)	As at 31 st March 2019 (Rs.)
1	A Description of Non-Current Asset (Disposal group)	-	-
2	a description of the facts and circumstances of the sale, or leading to the expected disposal, and the expected manner and timing of that disposal	-	-
3	the gain or loss recognized in accordance with paragraphs 20– 22 and, if not separately presented in the statement of profit and loss, the caption in the statement of profit and loss that includes that gain or loss	-	-

2.2 Ind AS 106: Exploration for Evolution of Mineral resources: This Ind AS 106 not applicable, the company is in the business of Infrastructure. Hence this Ind AS does not have any financial impact on the financial statements of the company.

2.3 Ind AS-16: Property, Plant and Equipment:

Items of Property, Plant and Equipment are stated at cost less accumulated depreciation.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labor, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in profit or loss.

Assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less cost of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units).

Depreciation on the fixed assets has been provided based on useful lives as prescribed under part C of the schedule II of the Companies act, 2013.

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate.

ARUNJYOTI BIO VENTURES LIMITED

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (up to) the date on which asset is ready for use (disposed of).

The Books of Accounts of company does not carry any Fixed Assets for the reporting Period, hence this accounting standard does not have financial impact on the financial statements of the company.

2.4 Impairment Assets (Ind AS 36)

The Company's non-financial assets, other than deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the statement of profit and loss. Impairment loss recognised in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

The books of accounts of the company doesn't carry any impairment of assets during the reporting period, hence this accounting standard does not have financial impact on the financial statements of the company.

2.5 Intangible assets (Ind AS 38):

Intangible assets are amortized over the estimated useful lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method are reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as

ARUNJYOTI BIO VENTURES LIMITED

appropriate, and are treated as change in accounting estimates. The amortization expense on intangible assets with finite useful lives is recognized in profit or loss.

The books of accounts of the company doesn't carry any Intangible assets during the reporting period, hence this accounting standard does not have financial impact on the financial statements of the company

2.6 Cash Flow Statement (Ind AS 7):

Cash flows are reported using the indirect method under Ind AS 7, whereby profit/(loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

- a). Non-cash items: Nil
- b). Changes in Liability Arising from Financing Activity

Particulars	01-Apr-19	Cash Flow	31-Mar-20
		(Net)	
Current Borrowings	-	-	-
Non-current Borrowings	-	-	-
Total	-	-	-

2.7 Operating Cycle:

The Company has adopted its normal operating cycle as twelve months based on the nature of products and the time between the acquisition of assets for processing and their realization, for the purpose of current / non-current classification of assets and liabilities.

2.8 Capital Work in Progress

The Books of Accounts of Company doesn't carry Capital work-in-progress during the reporting period.

2.9 Investments:

The Books of Accounts of Company doesn't carry any Investments during the reporting period.

2.10 Effects of changes in foreign Rates (Ind AS 21):

Foreign currency transactions are recorded at the exchange rates prevailing on the dates when the relevant transactions took place. Exchange difference arising on settled foreign currency transactions during the year and translation of assets and liabilities at the yearend are recognized in the statement of profit and loss.

In respect of Forward contracts entered into to hedge risks associated with foreign currency fluctuation on its assets and liabilities, the premium or discount at the inception of the contract is amortized as income or expense over the period of contract. Any profit or loss arising on the cancellation or renewal of forward contracts is recognized as income or expense in the period in which such cancellation or renewal is made.

The company has not entered any foreign exchange transactions during the reporting period, hence this accounting standard does not have financial impact on the financial statements.

2.11 Borrowing Costs (Ind AS 23):

Borrowing costs that are attributable to the acquisition or construction of qualifying assets up to the date of capitalization of such asset are capitalized as part of the cost of such assets. All other borrowing costs are charged to the Statement of Profit and Loss.

2.12 Revenue Recognition (Ind AS 18-Revenues):

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognized:

- a) Sales Revenue is recognized on dispatch to customers as per the terms of the order. Gross sales are net of returns and applicable trade discounts and excluding GST billed to the customers.

ARUNJYOTI BIO VENTURES LIMITED

- b) Subsidy from Government is recognized when such subsidy has been earned by the company and it is reasonably certain that the ultimate collection will be made.
- c) Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "other income" in the statement of profit and loss.
- d) All other incomes are recognized based on the communications held with the parties and based on the certainty of the incomes.

2.13 Accounting for Government Grants and Disclosure of Government Assistance (Ind AS 20):

Government grants:

Government grants are not recognised until there is reasonable assurance that the Company will comply with the conditions attached to them and that the grants will be received.

Government grants are recognised in the Statement of Profit and Loss on a systematic basis over the years in which the Company recognizes as expenses the related costs for which the grants are intended to compensate or when performance obligations are met.

Government grants, whose primary condition is that the Company should purchase, construct or otherwise acquire non-current assets and nonmonetary grants are recognised and disclosed as 'deferred income' under non-current liability in the Balance Sheet and transferred to the Statement of Profit and Loss on a systematic and rational basis over the useful lives of the related assets.

The benefit of a government loan at a below-market rate of interest and effect of this favorable interest is treated as a government grant. The loan or assistance is initially recognised at fair value and the government grant is measured as the difference between proceeds received and the fair value of the loan based on prevailing market interest rates and recognised to the income statement immediately on fulfillment of the performance obligations. The loan is subsequently measured as per the accounting policy applicable to financial liabilities.

The company has not received any Government Grants during the reporting period, hence this accounting standard does not have financial impact on the financial statements.

ARUNJYOTI BIO VENTURES LIMITED

2.14 Inventories (Ind AS 2):

Inventories at the yearend are valued as under:

Raw Materials, Packing Material, Components, Consumables and Stores & Spares	At Cost as per First in First Out Method (FIFO)
--	---

- Cost of Material excludes duties and taxes which are subsequently recoverable.
- Stocks at Depots are inclusive of duty, wherever applicable, paid at the time of dispatch from Factories.

2.15 Trade Receivables – Doubtful debts:

Provision is made in the Accounts for Debts/Advances which is in the opinion of Management are Considered doubtful of Recovery.

2.16 Retirement and other Employee Benefits:

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as expenditure, when an employee renders related service.

Gratuity liability is a defined benefit obligation and the cost of providing the benefits under this plan is determined on the basis of actuarial valuation at each year-end. Actuarial valuation is carried out for this plan using the projected unit credit method. Actuarial gains and losses for defined benefits plan is recognized in full in the period in which they occur in the statement of profit and loss.

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the year-end. Actuarial gains/losses are immediately taken to the

statement of profit and loss and are not deferred. The Company presents the leave as a current liability in the balance sheet, to the extent it does not have an unconditional right to defer its settlement for 12 months after the reporting date.

2.17 Ind AS 17- Leases

Finance charges in respect of finance lease obligations are recognized as finance costs in the statement of profit and loss. In respect of operating leases for premises, which are cancellable / renewable by mutual consent on agreed terms, the aggregate lease rents payable are charged as rent in the Statement of Profit and Loss.

2.18 Insurance Claims:

Insurance Claims are accounted for on the basis of claims admitted/excepted to be admitted and to the extent that the amount recoverable can be measured reliably and it is reasonable to expect ultimate collection.

2.19 Earnings per Share (Ind AS 33):

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Partly paid equity shares are treated as a fraction of an equity share to the extent that they are entitled to participate in dividends relative to a fully paid equity share during the reporting period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

2.20 Provisions, Contingent Liabilities and Contingent Assets (Ind AS 37):

The Company recognized provisions when there is present obligation as a result of past event and it is probable that there will be an outflow of resources required to settle the obligation in respect of which a reliable estimate can be made. A disclosure for Contingent liabilities is made

ARUNJYOTI BIO VENTURES LIMITED

when there is a possible obligation or present obligations that may, but probably will not, require an outflow of resources. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates. Contingent assets are neither recognized nor disclosed in the financial statements.

Contingent Liabilities not provided for and commitments:

(In Rupees)

Nature of Contingent Liability	March 31, 2020	March 31, 2019
i. Unexpired guarantees issued on behalf of the company by Banks for which the Company has provided counter guarantee	NIL	NIL
ii. Bills discounted with banks which have not matured	Nil	Nil
iii. Corporate Guarantees issued by Company on behalf of others to Commercial Banks & Financial Institutions	Nil	Nil
iv. Collateral Securities offered to Banks for the limit Sanctioned to others	Nil	Nil
v. Legal Undertakings given to Customs Authorities for clearing the imports	Nil	Nil
vi. Claims against the company not acknowledged as debts		
a. Excise	NIL	NIL
b. Sales Tax	NIL	NIL
c. Service Tax	Nil	Nil
d. Income Tax	NIL	NIL
e. Civil Proceedings	NIL	NIL
f. Company Law Matters	Unascertainable	Unascertainable
g. Criminal Proceedings	Unascertainable	Unascertainable
h. Others	Nil	Nil
vii. Estimated amounts of contracts remaining to be executed on Capital Account and not provided for	Nil	Nil

2.21 Prior Period and Extraordinary and Exceptional Items:

- (i) All Identifiable items of Income and Expenditure pertaining to prior period are accounted through "Prior Period Items".
- (ii) Extraordinary items are income or expenses that arise from events or transactions that are clearly distinct from the ordinary activities of the enterprise and, therefore, are not expected to recur frequently or regularly. The nature and the amount of each extraordinary item be separately disclosed in the statement of profit and loss in a manner that its impact on current profit or loss can be perceived.
- (iii) Exceptional items are generally non-recurring items of income and expenses within profit or loss from ordinary activities, which are of such, nature or incidence.

2.22 Financial Instruments (Ind AS 107 Financial Instruments: (Disclosures)

I. Financial assets:

A. Initial recognition and measurement

All financial assets and liabilities are initially recognized at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, which are not at fair value through profit or loss, are adjusted to the fair value on initial recognition.

a) Financial assets carried at amortized cost (AC)

A financial asset is measured at amortized cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

b) Financial assets at fair value through profit or loss (FVTPL)

A Financial asset which is not classified as AC or FVOCI are measured at FVTPL e.g. investments in mutual funds. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss is recognised in profit or loss and presented net in the Statement of Profit and Loss within other gains/(losses) in the period in which it arises.

c) Financial assets at fair value through other comprehensive income (FVTOCI)

ARUNJYOTI BIO VENTURES LIMITED

A financial asset is measured at FVTOCI if it is held within a business model whose Objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

B. Investments in subsidiaries

The Company has accounted for its investments in subsidiaries at cost and not adjusted to fair value at the end of each reporting period. Cost represents amount paid for acquisition of the said investments.

II. Financial Liabilities

A. Initial recognition

All financial liabilities are recognized at fair value.

B. Subsequent measurement

Financial liabilities are carried at amortized cost using the effective interest method. For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

1. Operating Segments (IndAS 108)

The company is in the business Infrastructure. Hence IND AS 108 is not applicable.

2. Events Reporting Period (IndAS-10)

An entity shall adjust the amounts recognized in its financial statements to reflect adjusting events after the reporting period.

3. Construction Contracts (Ind AS -11): The company does not have any construction contracts for the year ended.

4. Income Taxes (IndAS 12)

Tax Expense comprises of current and deferred tax.

- **Current Tax:**

Current Tax on Income is determined and provided on the basis of taxable income computed in accordance with the provisions of the Income Tax Act, 1961.

ARUNJYOTI BIO VENTURES LIMITED

In the year in which 'Minimum Alternative Tax '(MAT) on book profits is applicable and paid, eligible MAT credit equal to the excess of MAT paid over and above the normally computed tax, is recognized as an asset to be carried forward for set off against regular tax liability when it is probable that future economic benefit will flow to the Company within the MAT credit Entitlement period as specified under the provisions of Income Tax Act, 1961.

- **Deferred Taxes:**

Deferred tax liabilities are recognized for all timing differences. Deferred tax assets are recognized for deductible timing differences only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

At each reporting date, the Company re-assesses unrecognized deferred tax assets. It recognizes unrecognized deferred tax asset to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized.

The carrying amount of deferred tax assets are reviewed at each reporting date. The Company writes-down the carrying amount of deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

5. Retirement and other Employee Benefits:

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as expenditure, when an employee renders related service.

Gratuity liability is a defined benefit obligation and the cost of providing the benefits under this plan is determined on the basis of actuarial valuation at each year-end. Actuarial valuation is carried out for this plan using the projected unit credit method. Actuarial gains and losses for

ARUNJYOTI BIO VENTURES LIMITED

defined benefits plan is recognized in full in the period in which they occur in the statement of profit and loss.

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the year-end. Actuarial gains/losses are immediately taken to the statement of profit and loss and are not deferred. The Company presents the leave as a current liability in the balance sheet, to the extent it does not have an unconditional right to defer its settlement for 12 months after the reporting date.

ARUNJYOTI BIO VENTURES LIMITED

Amount Rs.

Note 1: Property, Plant Equipment		Land	Buildings	Plant & Machinery	Electrical Installations	Lab Equipments	Computers	Office Equipment	Furniture & Fixtures	Vehicles	Total
Particular	Cost/Deemed Cost:										
	at 1st April 2018	-	-	-	-	-	-	-	-	-	-
	Additions	-	-	-	-	-	-	-	-	-	-
	Deletions	-	-	-	-	-	-	-	-	-	-
	As at March 2019	-	-	-	-	-	-	-	-	-	-
	Additions	-	-	-	-	-	-	-	-	-	-
	Deletions	-	-	-	-	-	-	-	-	-	-
	As at March 2020	-	-	-	-	-	-	-	-	-	-
	Depreciation/Impairment										
	at 1st April 2018	-	-	-	-	-	-	-	-	-	-
	Depreciation for the year	-	-	-	-	-	-	-	-	-	-
	Disposals	-	-	-	-	-	-	-	-	-	-
	Impairment	-	-	-	-	-	-	-	-	-	-
	As at March 2019	-	-	-	-	-	-	-	-	-	-
	Depreciation for the year	-	-	-	-	-	-	-	-	-	-
	Disposals	-	-	-	-	-	-	-	-	-	-
	Impairment	-	-	-	-	-	-	-	-	-	-
	As at March 2020	-	-	-	-	-	-	-	-	-	-
	Net Book Value										
	As at March 2020	-	-	-	-	-	-	-	-	-	-
	As at March 2019	-	-	-	-	-	-	-	-	-	-

Note 1(a): Other Intangible Assets

Computer Software		Patentents	Trade marks	Total
Particular	Cost/Deemed Cost:			
	at 1st April 2018	-	-	-
	Additions	-	-	-
	Deletions	-	-	-
	As at March 2019	-	-	-
	Additions	-	-	-
	Deletions	-	-	-
	As at March 2020	-	-	-
	Depreciation/Impairment			
	at 1st April 2018	-	-	-
	Depreciation for the year	-	-	-
	Disposals	-	-	-
	As at March 2019	-	-	-
	Depreciation for the year	-	-	-
	Disposals	-	-	-
	Impairment	-	-	-
	As at March 2020	-	-	-
	Net Book Value			
	As at March 2020	-	-	-
	As at March 2019	-	-	-

ARUNJYOTI BIO VENTURES LIMITED

Notes annexed to and forming part of the Financial Statements

Note.2 : Invesments

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
	Non Current		
1	Investments in quoted shares	-	-
2	investment in unquoted shares of subsidiaries	-	-
3	invetment in Joint Ventures	-	-
4	investment in Preference Shares	-	-
5	Investment in partnerships	-	-
	Total	-	-
	Current		
1	Investments in quoted shares	-	-
2	investment in unquoted shares of subsidiaries	-	-
3	invetment in Joint Ventures	-	-
4	investment in Preference Shares	-	-
5	Investment in partnerships	-	-
	Total	-	-

Note 3:Trade Receivables

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
	Non Current		
A	<u>Secured and considered good:</u>		
	-From Related party	-	-
	-From Others	-	-
B	<u>Unsecured and considered good:</u>		
	-From Related party	-	-
	-From Others	-	-
C	<u>Doubtful:</u>		
	-From Related party	-	-
	-From Others	-	-
	Less: allowance for doubtful debts	-	-
	Total	-	-
	Current:		
A	<u>Secured and considered good:</u>		
	-From Related party	-	-
	-From Others	-	-
B	<u>Unsecured and considered good:</u>		
	-From Related party	-	-
	-From Others	2,67,25,481	2,35,59,851
C	<u>Doubtful:</u>		
	-From Related party	-	-
	-From Others	-	-
	Less: allowance for doubtful debts	-	-
	Total	2,67,25,481	2,35,59,851

ARUNJYOTI BIO VENTURES LIMITED

Note 4: Loans

S.No	Particulars	As at March 31, 2020	As at March 31, 2019
	<u>Non Current:</u>		
A	<u>Loans :</u>		
1	To related parties	-	-
2	to other boady corporate	-	-
3	to employees	-	-
4	Security Deposits:	1,49,71,192.00	1,49,71,192.00
5	Less: allowances for Doubfull loans	-	-
	Total Loans	1,49,71,192.00	1,49,71,192.00
	<u>Notes:</u>		
1	Considered fgood	-	-
2	Considered Doubt full, Provided:	-	-
3	To related parties	-	-
4	to other boady corporate	-	-
5	to employees	-	-
	Total	2,99,42,384.00	2,99,42,384.00
	<u>Current:</u>		
A	<u>Loans :</u>		
1	To related parties	-	-
2	to other boady corporate	-	-
3	to employees	-	-
4	Security Deposits:	-	-
5	Less: allowances for Doubfull loans	-	-
	Total	-	-
	<u>Notes:</u>		
1	Considered fgood	-	-
2	Considered Doubt full, Provided:	-	-
3	To related parties	-	-
4	to other boady corporate	-	-
5	to employees	-	-

ARUNJYOTI BIO VENTURES LIMITED

Note 5: Other Financial Assets

S.No	Particulars	As at March 31, 2020	As at March 31, 2019
	<u>Non Current</u>		
1	Export benefits and entitlements	-	-
2	Insurance claims receivable	-	-
3	Advances towards equity/preference share capital	-	-
4	<u>Derivative instruments:</u>		
a	Derivative instruments at fair value	-	-
b	Cash flow hedges	-	-
c	Foreign exchange forward contracts	-	-
	Total Derivative Instruments at fair value through OCI	-	-
	Derivative instruments at fair value through profit or loss through OCI:		
	Derivatives not designated as hedges		
	Foreign exchange forward contracts		
	Embedded derivatives		
	Total derivative instruments at fair value through profit or loss	-	-
	Total Financial Assets	-	-
	<u>Current</u>		
1	Export benefits and entitlements		
2	Insurance claims receivable		
3	Advances towards equity/preference share capital		
4	<u>Derivative instruments:</u>		
a	Derivative instruments at fair value		
b	Cash flow hedges		
c	Foreign exchange forward contracts		
	Total Derivative Instruments at fair value through OCI	-	-
	Derivative instruments at fair value through profit or loss through OCI:		
	Derivatives not designated as hedges		
	Foreign exchange forward contracts		
	Embedded derivatives		
	Total derivative instruments at fair value through profit or loss	-	-
	Total Financial Assets	-	-

ARUNJYOTI BIO VENTURES LIMITED

Note 6: Income Taxes

(Amt. in Rs.)

S.No	Particulars	As at March 31, 2020	As at March 31, 2019
	a). Current Tax liability		
	Opening Balance		
	Add: Current tax payable for the year	-	-
	Less: Taxes Paid	-	-
	Closing balances	-	-
	b). Current Tax Asset		
	Opening Balance		
	Add: Taxes paid/TDS Receivable	-	-
	Less: Current tax payable for the year	-	-
	Closing Balance	-	-
	c). Differed Tax Asset		
	Differed tax Asset - (A)	-	-
	Provision for Employees	-	-
	Waranty Provisions	-	-
	Loss allowance on financial and Contract Assets	-	-
	Others	-	-
	Sub Total (A)	-	-
	Differed tax Liability- (B)		
	on Written down value of fixed assets	-	-
	Others	-	-
	Sub Total (B)	-	-
	Total (A-B)	-	-

Note 7: Other Non Current Assets

(Amt in Rs.)

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
A	<u>Other Non-Current Assets</u>		
	Capital Advances	-	-
	Advances other than capital advances	-	-
	<u>Security Deposits:</u>		
	Government Authorities - Electricity Dept	-	-
	— Advances to Related Parties	-	-
	— Other Advances	-	-
	Others - unsecured	-	-
	Total of Other Non-current Assets	-	-

Note 8: Inventories

(Amt. in Rs.)

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
1	Raw Material	-	-
2	Packing Material	-	-
3	Work In Process	-	-
4	Finished Goods	2,96,484	52,89,553
5	Consumables & Stores and Spares	-	-
6	Property under Development	-	-
	Total Inventories	2,96,484	52,89,553

ARUNJYOTI BIO VENTURES LIMITED

Notes 8.1: Disclosure of Inventories pledged as security for liabilities as follows

S.No		Carrying Amount Rs.	Security Pledged Against
A	As at 31st March 2020		
a	Raw Material		
b	Work In Process		
c	Finished Goods		
B	As at 31st March 2019		
a	Raw Material		
b	Work In Process		
c	Finished Goods		
	Total Inventories	-	-

Note 9: Cash and Cash Equivalents

(Amt. in Rs.)

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
1	Cash and Cash Equivalents (Note 9.1)	7,511	2,296
2	Bank Balances other than Cash and Cash Equivalents	1,11,68,888	34,55,929
	Total Cash and Cash Equivalents	1,11,76,399	34,58,225

Notes:

- In the Balance sheet Cash comprises cash and demand deposits.
- Cash equivalents are held for the purpose of short term cash commitments rather than for investment or other

Note 9.1: Cash and Cash Equivalents

(Amt. in Rs.)

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
	Bank and Cash Balances		
	On Current Accounts:		
1	SBI	-	-
2	Cheques/dafts on hand	-	-
3	Cash on hand	-	-
	Total Cash and Cash Equivalents	-	-

Note 10: Other Current Assets

(Amt in Rs.)

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
	Other Current Assets		
1	Capital Advances:	-	-
	Advances to Plant and Machinery	-	-
2	Advances other than capital advances:	-	-
	MAT Credit Entitlement	45,710	84,319
3	Security Deposits	-	-
4	Advances to Related Parties	-	-
5	Other Advances:	-	-
	GST Input	56,23,328	72,83,938
	Interest Receivable	-	-
	Advances to Employees	1,55,481	1,91,401
	Total of Other current Assets	58,24,519	75,59,658

ARUNJYOTI BIO VENTURES LIMITED

Note 10.1: Non Current Assets Classified as Held for Sale

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
	Non-Curret Assets		
1	Plant, Propety and Equipment	-	-
2	Others	-	-
	Total Non Current Assets Clasiffied as Held for Sale	-	-

Note 12: Borrowings

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
	Non-Current:		
1	Bonds	-	-
2	Debentures(Secured)	-	-
3	Term loans:	-	-
i	Secured	-	-
	From Bank		
	Loan From Vijaya lakshmi Vilas Bank Ltd (The loan account became NPA and company defaulted in making payment)	-	-
	Loan From Indian Overseas Bank (The loan account became NPA and company defaulted in making payment)	-	-
ii	Unsecured	-	-
iii	From banks	-	-
iv	Working Capital	-	-
v	Deferred payment liabilities	-	-
vi	Other Loans	-	-
vii	-Finance lease obligations	-	-
viii	- Preference shares	-	-
ix	Interest-free sales Tax deferral loan from state Govt.	-	-
4	Unsecured Loans		
	Loans fom Individuals other than		
i	Banks	-	-
ii	Loans from Related Companies	-	-
	Total	-	-
	Current:		
1	Bonds	-	-
2	Debentures(Secured)	-	-
3	Term loans:	-	-
i	Secured	-	-
ii	Unsecured	-	-
iii	From banks	-	-
iv	Working Capital	-	-
v	Deferred payment liabilities	-	-
vi	Other Loans	-	-
vii	-Finance lease obligations	-	-
viii	- Preference shares	-	-
ix	Interest-free sales Tax deferral loan from state Govt.	-	-
4	Unsecured Loans		
	Loans from Related parties	-	-
5	Cash Credit		
i	Lakshmi Vilas Bank-2881 (The Company defaulted in payment of loan interest and the CC account became NPA)	-	-
	Total	-	-

ARUNJYOTI BIO VENTURES LIMITED

Note 13: Trade Payables

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
	Non Current:		
A	Trade payables		
	Dues to Micro, Small and Medium Enterprises	-	-
	Dues to other than Micro, Small and Medium Enterprises	-	-
	Sub Total	-	-
B	Trade payables		
	Dues to Micro, Small and Medium Enterprises	-	-
	Dues to other than Micro, Small and Medium Enterprises	-	-
	Total	-	-
	Current:		
A	Trade payables		
	Dues to Micro, Small and Medium Enterprises	-	-
	Dues to other than Micro, Small and Medium Enterprises	-	-
	Sub Total	-	-
B	Trade payables		
	Dues to Micro, Small and Medium Enterprises	-	-
	Dues to other than Micro, Small and Medium Enterprises	2,18,42,239	2,10,57,322
	Total	2,18,42,239	2,10,57,322

Note: Dues to micro and small enterprises - As per Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED' Act) This information has been determined to the extent such parties have been identified on the basis of information available with the Company

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
	Principal amount remaining unpaid to any supplier as at the end of the year.	-	-
	Amount of interest due remaining unpaid to any supplier as at the end of the year	-	-
	Amount of interest paid under MSMED Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during the year.	-	-
	Amount of interest due and payable for the period of delay in making payment (where the principal has been paid but interest under the MSMED Act, 2006 not paid)	-	-
	Amount of interest accrued and remaining unpaid at the end of year.	-	-
	Amount of further interest remaining due and payable even in the succeeding year	-	-

ARUNJYOTI BIO VENTURES LIMITED

Note 14: Other Financial Liabilities

S.No		As at Mar 31, 2020	As at March 31, 2019
	Non Current:		
1	Investor education protection fund		
4	Others:		
i	Retention money for capital projects	-	-
ii	Payable towards capital expenditure	-	-
iii	Payable towards Services received	-	-
iv	Payable towards other expenses	-	-
v	Interest accrued but no due on borrowings	-	-
	Total	-	-
	Current		
1	Current Maturities of Long Term Borrowings	-	-
2	Current Maturities of finance lease obligation	-	-
3	Investor education protection fund	-	-
4	Others:		
i	Retention money for capital projects	-	-
ii	Payable towards capital expenditure	-	-
iii	Payable towards Services received	-	-
iv	Payable towards other expenses	-	-
v	Interest accrued but no due on borrowings	-	-
	Total	-	-

Note 15: Provisions

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
	Non Current:		
	a). Provision for Employee Benefits		
	For Provident Fund	-	-
	For gratuity	-	-
	Provision for compensated absences		
	b). Others	-	-
	Service Warranties	-	-
	Statutory Dues	-	-
	Legal Claims	-	-
	Total	-	-
	Current:		
	a). Provision for Employee Benefits		
	For Provident Fund	-	-
	For gratuity	-	-
	Provision for compensated absences		
	b). Others	-	-
	Service Warranties	-	-
	Statutory Dues	2,88,319	84,319
	Legal Claims	-	-
	Total	2,88,319	84,319

ARUNJYOTI BIO VENTURES LIMITED

Note 16 : Other current Liabilities

S.No	Particulars	As at Mar 31, 2020	As at March 31, 2019
	a). Revenue Received in Advance		
	Advances From customers	-	-
	b). Other Payables		
	TDS Payable	65,063	1,40,427
	Income Tax Payable	-	-
	Service Tax Payable	-	-
	Listing fee, Custody Fee, Issuer Fee	-	-
	Provision for Employee Benefit Expenses	-	-
	Other Expenses Payable	1,79,68,940	1,58,47,616
	Audit fee payable	1,00,000	-
	Total	1,81,34,003	1,59,88,043

Note 17: Revenue from operations

		(Amt. in Rs.)	
Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019	
A	Revenue from contracts with customers disaggregated based on nature of product or services		
	Revenue from Sale of Products		
	a). Sale of Manufactured Goods	7,30,88,613	3,71,74,710
	b). Stock in Trade	-	-
	Net Revenue	7,30,88,613	3,71,74,710
	Revenue from Sale Service		
	a). Software services	-	-
	b). Other Services	-	-
	Sub total	-	-
	Other Operating Revenues		
	a). Export Incentives		
	b). Royalty Received		
	From subsidiaries and associates		
	From others		
	c). Scrap Sale		
	d). Others		
	Sub total	-	-
	Total Revenue from Operations	7,30,88,613	3,71,74,710

ARUNJYOTI BIO VENTURES LIMITED

B	Disaggregated revenue information		
	Revenue from contracts with customers disaggregated based on geography		
	a). Domestic	-	-
	b).Export	-	-
		-	-
	C)Reconciliation of Gross Revenue from Contracts With Customers		
	Gross Revenue	-	-
	Less: Discount		
	Less: Returns		
	Less: Price Concession		
	Less: Incentives and performance bonus		
	Less: Goods and Service Tax	-	-
	Net Revenue recognised from Contracts with Customers	-	-

C1 Terms conditions on performance warranty

C2 Credit period

C3 The Company does not have any remaining performance obligation as contracts entered for sale of goods are for a shorter duration. There are no contracts for sale of services wherein, performance obligation is unsatisfied to which transaction price has been allocated.

Note 18: Other Income

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
Interest income		
a).Financial assets mandatorily measured at fair value through profit or loss	-	-
b). Interest income on financial assets fair valued through other comprehensive income	-	-
-Non Convertible debentures	-	-
c). Financial assets carried at amortised cost		
Tax free bonds and government bonds	-	-
Deposits with banks and others	-	-
Sub total (i)	-	-
Dividend Income		
a).Investments mandatorily measured at fair value through profit or loss	-	-
b).Equity investment designated at fair value through other comprehensive income	-	-
Sub total (ii)	-	-
Unwinding of discount on security deposits(iii)	-	-
Government grants (iv)	-	-
Rental income on Investment Properties (v)	-	-
Discount Received(vi)	28,293	15,627
Total(i+ii+iii+iv+v+vi)	28,293	15,627

ARUNJYOTI BIO VENTURES LIMITED

Note 19: Net gain/(Loss) on de-recognition of financial assets at amortised cost

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
Profit on sale of land and buildings	-	-
Written off of liability	-	-
Total Gain	-	-

Note 20: Net gain/(Loss) on reclassification of financial assets

Deposits with banks and others	For the year ended March 31, 2020	For the year ended March 31, 2019
Profit on sale of land and buildings	-	-
Written off of liability	-	-
Total Gain	-	-

Note 21: Cost of Material Consumed

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
A. Raw Material Consumed		
Raw materials at the beginning of the year	52,89,553	-
Add: Purchases During the year	5,59,03,935	3,67,13,180.0
Less: Raw materials at the end of the year	2,96,484	52,89,553.0
Total cost of raw material consumed	6,08,97,004	3,14,23,627
(Write down value of inventories Rs.0 and written down value of material due to obsolescence Rs.0 these amount included in the cost material consumed)		
B). Packing Material		
Packing materials at the beginning of the year	-	-
Add : Purchases During the year		
Less: Packing materials at the end of the year	-	-
Total cost of packing materials consumed (B)	-	-
Total cost of Materials consumed (B)	6,08,97,004	3,14,23,627

Note 22 : Changes in inventories of finished goods, work-in-progress and stock-in-trade

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
Opening Balance		
Finished Goods	-	-
Work in Progress	-	-
Stock in Trade (Including Goods in Transit)	-	-
Spares and Consumables	-	-
Total Opening Balnces	-	-
Closing Balance		
Finished Goods	-	-
Work in Progress	-	-
Stock in Trade (Including Goods in Transit)	-	-
Spares and Consumables	-	-
Total Closing Balance	-	-
Total Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-

ARUNJYOTI BIO VENTURES LIMITED

Note 23 Employee Benefits

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
Managerial Remuneration	12,59,000	12,32,500
Salaries, Wages, Bonus etc.	18,74,436	30,49,931
Contribution to P.F, E.S.I and Other Statutory Funds	-	-
Employee share based payment expenses	-	-
Gratuity	-	-
Leave compensation	-	-
Post-employment pension benefits	-	-
Post-employment medical benefits	-	-
Staff welfare expenses	1,070	17,702
Total Employee benefits	31,34,506	43,00,133

Note 24: Finance Cost

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
Interest and finance charges on financial liabilities carried at amortised cost		
a). Interest on Bank Borrowings	-	-
b). Interest on Bill Discounting	-	-
c). Other Interest Expenses(Bank Charges)	1,929	1,431
Less: Amount Capitalised		
Total Interest on financial liabilities carried at amortised cost	1,929	1,431
Interest on Trade payables (as per MSME Act)	-	-
Interest on delayed payment of statutory dues	-	-
Unwinding of discount on provision	-	-
Exchange difference regarded as adjustment to borrowing costs	-	-
Dividend on redeemable preference shares (including dividend distribution tax)	-	-
Total Finance Cost	1,929	1,431

Note 25 Depreciation and Amortisation Expenses

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
Depreciation on plant, property and equipment	-	-
Depreciation on Investment properties	-	-
Amortisation on Intangible assets	-	-
Total depreciation and Amortisation expenses	-	-

ARUNJYOTI BIO VENTURES LIMITED

Note 26 : Other expenses

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
Audit Fees	-	-
Advertisement & Business Promotion Expenses	41,327	71,974
Flat Maintenance	-	-
Repairs & Maintenance	-	-
Bank Charges	-	-
Stock Exchange Listing Charges	3,77,740	33,740
Travelling & Conveyance Expenses	7,20,313	4,07,488
ROC Charges	-	-
Printing & Stationery	896	33,569
Rent	57,600	2,01,600
Telephone Expense	22,433	18,796
Paper & Expenses	-	-
Other General Expenses	93,296	59,267
Secretarial Audit Fee	-	-
Electricity Charges	1,626	1,228
Commission/Brokerage charges	45,000	25,000
Office Maintenance	1,200	7,517
Professional and Consultancy	1,90,420	1,15,800
Turnover Discount	57,42,860	-
Interest on TDS	15,557	-
Rates & Taxes	3,64,163	919
Total	76,74,431	9,76,898

26.1 Payment to Auditors

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
As An Auditor		
- Audit Fees	1,00,000	50,000
- Tax Audit	-	-
- Limited Review	-	-
In Other Capacity		
- Taxation Matters	-	-
- Company Law matters	-	-
- Certification matters	-	-
- Reimbursement of Expenses	-	-
Total Payment to Auditor	1,00,000	50,000

26.2 Corporate Social Responsibility(CSR) Not Applicable to this period

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
Amount required to be spent as per Section 135 of the Companies Act, 2013	-	-
Amount spent during the year on:	-	-
	-	-

ARUNJYOTI BIO VENTURES LIMITED

Notes annexed to and forming part of the Financial Statements

Note 11: Equity share capital

a. Equity share capital	(Amt. in Rs.)			
	As at Mar 31, 2020		As at March 31, 2019	
	No. of Shares	Amount in Rs.	No. of Shares	Amount in Rs.
Authorised				
Equity shares of Rs. 10 each	35,00,000	3,50,00,000	35,00,000	3,50,00,000
Issued				
Equity shares of Rs. 10 each	20,70,900	2,07,09,000	20,70,900	2,07,09,000
Subscribed and Paid-up				
Equity shares of Rs. 10 each fully paid-up	20,70,900	2,07,09,000	20,70,900	2,07,09,000
Total	20,70,900	2,07,09,000	20,70,900	2,07,09,000

*2070900 shares of Rs. 10 each allotted as fully paid up pursuant to contract without payment being received in cash.

b. Reconciliation of the number of equity shares outstanding and the amount of share capital	As at Mar 31, 2020		As at March 31, 2019	
	No. of Shares	Amount	No. of Shares	Amount
Equity Shares				
Issued and Subscribed:				
Shares outstanding at the beginning of the year	20,70,900	2,07,09,000	20,70,900	2,07,09,000
Add: Issued During the year for cash	-	-	-	-
Add: Shares issued at ESOP trust	-	-	-	-
Shares outstanding at the end of the year	20,70,900	2,07,09,000	20,70,900	2,07,09,000

c. Terms / rights attached to equity Shares

The company has one class of equity shares having a par value of Rs.10 per share. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion to their shareholdings.

d. Shares reserved for issue underwriter options

Nil

e. Detail of Rights Issues

Nil

f. details of shares held by Holding/Ultimatley Holding Company

Nil

g. Details of shares issued for consideration other than cash

Nil

h. Shares in the company held by each shareholder holding more than 5 percent

Name of the Shareholder	As at Mar 31, 2020		As at March 31, 2019	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
P SRINIVASA RAO	1,25,815	6.08%	1,25,815	6.08%
P LEELA MADHURI DEVI	1,45,984	7.05%	1,32,802	6.41%
RAGHU RAM RENDUCHINTALA	2,05,954	9.95%	2,05,954	9.95%
PRAVEEN KUMAR PABBATHI	1,04,076	5.03%	1,04,076	5.03%

*Includes 10 Equity shares of Rs. 10 each fully paid up held by nominee.

i. Dividend Declaration Details

Particulars	Amount in Rs.	
	As at Mar 31, 2020	As at March 31, 2019
Cash Dividend Declared for the Year 31 march 2019	-	-
Dividend Distribution Tax on fianl Dividend	-	-
Interim Dividend for the year ended on 31March 2020		
Total	-	-
Proposed Dividend on Equity Shares		
Final Dividend for the year ended 31 March 2020		
Distribution Tax on Proposed Dividend		
Total	-	-

ARUNJYOTI BIO VENTURES LIMITED

Note 11.1 Other equity

	As at Mar 31, 2020	As at March 31, 2019
Capital Reserve:		
Balance at the beginning of the year	23,33,750	23,33,750
Add: Addition During the Year	-	-
Balance at the end of the year	23,33,750	23,33,750
Securities Premium:		
Balance at the beginning of the year	-	-
Add: Securities Premium on shares issued during the year	-	-
Balance at the end of the year	-	-
Retained earnings		
Balance at the beginning of the year	(53,33,955)	(57,72,203)
Add: Addition During the Year	10,20,718	4,38,248
Less: TDS Written off	-	-
Balance at the end of the year	(43,13,237)	(53,33,955)
Total other Equity	(19,79,487)	(30,00,205)

Note 11.2 Other Reserves

	As at Mar 31, 2020	As at March 31, 2019
Debentures Redemption Reserves:		
Balance at the beginning of the year	-	-
Add: Addition during the Year	-	-
Balance at the end of the year	-	-
Capital Redemption Reserves:		
Balance at the beginning of the year	-	-
Add: Addition during the Year	-	-
Balance at the end of the year	-	-
Investment Fluctuation Reserves:		
Balance at the beginning of the year	-	-
Add: Addition during the Year	-	-
Balance at the end of the year	-	-
Total Other Reserves	-	-

28. Related Party Disclosures (Ind AS 24):

Related Party disclosures required as per Accounting Standard (Ind AS-24) on "Related Party disclosures" issued by the Institute of Chartered Accountants of India, are as below:

a) Names of related parties and the Description of Relationship:

S. No	Name of Related Parties	Relationship
1	Venkatarama Rao Polsani	Director
2	Pabbathi Praveen Kumar	Wholetime Director
3	Manda Aditya Vardhan Reddy	Director
4	Vanaja Kumari Dokiparthi	Director
5	Babulal Raja Kumar	Wholetime Director
6	Konadari Chandra Shekar	Director

ARUNJYOTI BIO VENTURES LIMITED

b) Related Party Transactions during the year: NIL

29. Consolidated and Separate Financial Statement (Ind AS 27):

The company has no subsidiary companies for the current reporting period. Hence consolidate and separate financial statement are not applicable.

30. Investments in Associates (Ind AS 28):

The company has not made any investments in any of its associates during the reporting period. This accounting standard has no financial impact on the financial statements for the current reporting period.

31. Interest in Joint Ventures (Ind AS 31):

The company has no interest in any Joint ventures. This accounting standard has no financial impact on the financial statements for the current reporting period.

32. Derivative instruments and un-hedged foreign currency exposure:

a) There are no outstanding derivative contracts as at March 31, 2020 and March 31, 2019.

b) Particulars of Un-hedged foreign currency exposure is: Nil

33. Secured Loans:

There are no Secured loans for the reporting period.

34. Confirmation of Balances:

Confirmation letters have been issued by the company to Trade Receivables, Trade Payables, Advances to suppliers and others advances requesting that the confirming party responds to the company only if the confirming party disagrees with the balances provided in the request and however the company has not received any letters on disagreements.

ARUNJYOTI BIO VENTURES LIMITED

35. Net Current Assets:

S. No	Particulars	As at 31 st March 2020	As at 31 st March 2019
A	Current Assets:		
1	Inventories	2,96,484	52,89,553
2	Trade Receivables	2,67,25,481	2,35,59,851
3	Cash and Cash equivalent	1,11,76,399	34,58,225
4	Loans	-	-
5	Other Current Asset	58,24,519	75,59,658
	Total Current Assets	4,40,22,882	3,98,67,287
B	Current Liabilities:		
1	Borrowings	-	-
2	Trade Payables	2,18,42,239	2,10,57,322
3	Other Current Liabilities	1,81,34,003	1,59,88,043
4	Short term provisions	2,88,319	84,319
5	Current Tax Liability	-	-
	Total Current liabilities	4,02,64,561	3,71,29,684
C	Current Assets-Current Liabilities	37,58,321	27,37,603

36. Revenue from Operations:

S. No	Particulars	As at 31 st March 2020	As at 31 st March 2019
1	Sale of goods:		
	Sale of Manufactured Products	7,30,88,613	3,71,74,710
	Stock in trade	-	-
	Total	-	-
2	Revenue from Sale of Service	-	-
3	Other Operating Revenues	-	-

ARUNJYOTI BIO VENTURES LIMITED

37. Revenue Reconciliation:

S. No	Particulars	As at 31 st March 2020	As at 31 st March 2019
1	Sale of Products ^o		
	Domestic	7,46,71,281	3,89,06,903
	Exports	-	-
	Gross Revenue	-	-
	Less: Discount	-	-
	Less: Returns	15,82,668	17,32,193
	Less: price Concession	-	-
	Less Incentives and Performance bonus	-	-
	Less: Goods and service Tax	-	-
	Net Revenues recognized from contracts with customers	7,30,88,613	3,71,74,710

38. Other Income:

S. No	Particulars	As at 31 st March 2020	As at 31 st March 2019
1	Interest on Deposits with With banks and Others.	-	-

39. a) Basic Earnings Per Share (continued operations): There are no discontinued operations hence, EPS is presented for continued operations only.

(Amount in Rs.)

Particulars	Year ended March 31, 2020	Year ended March 31, 2019
Nominal Value of Equity Shares (Rupees per Share fully paid-up) (A)	10	10
Profit after Tax (in Rs.) (B)	10,20,718	4,38,248
No of Shares outstanding as on 01.04.2019	20,70,900	20,70,900
Shares Issued During the Year	-	-
Weighted average number of Equity shares outstanding at the end of the year (C)	20,70,900	20,70,900
Earnings Per Share (in Rs.) – Basic (D = B÷C)	0.49	0.21

ARUNJYOTI BIO VENTURES LIMITED

- b). Diluted earnings per share (continued operations): There are no discontinued operations hence, EPS is presented for continued operations only.

(Amount in Rs.)

Particulars	Year ended March 31, 2020	Year ended March 31, 2019
Nominal Value of Equity Shares (Rupees per Share fully paid-up) (A)	10	10
Profit after Tax (in Rs.) (B)	10,20,718	4,38,248
No of Shares outstanding as on 01.04.2019	20,70,900	20,70,900
Shares Issued During the Year	-	-
Weighted average number of Equity shares outstanding at the end of the year (C)	20,70,900	20,70,900
Dilutive Shares (D)	NIL	NIL
Earnings Per Share (in Rs.) – Diluted (E) (E = B÷C)	0.49	0.21

40. Details of Loans given, Investments made and Guarantee given covered Under Section 186(4) of the Companies Act, 2013.

The company has not extended any Corporate Guarantees in respect of loans availed by any company/firm as at March 31, 2020

41. Auditors' Remuneration:

(Amount in Rs.)

Particulars	March 31, 2020	March 31, 2019
Fees towards*		
Statutory Audit	1,00,000	50,000

*The fees is exclusive of GST

ARUNJYOTI BIO VENTURES LIMITED

42. Dues to Micro Small and Medium Enterprises:

Disclosure required as per section 22 of the Micro, Small and Medium Enterprise Development Act, 2006 (MSMED Act.) as at 31.03.2020.

SL No	Description	March 31, 2020
1	Principal amount due to suppliers under MSMED	NIL
2	Interest accrued and due to suppliers covered under MSMED on the above amount, unpaid	NIL
3	Payment made to suppliers (with Interest) beyond the appointed day during the year.	NIL
4	Payment made to suppliers (other than interest) beyond the appointed day during the previous year	NIL
5	Interest paid to suppliers covered under MSMED	NIL
6	Interest due & Payable to suppliers covered under MSMED Act., towards payments already made.	NIL

The information has been given in respect of such vendors to the extent they could be identified as micro and small enterprises on the basis of information available with company.

43. Financial Risk Management

In course of its business, the company is exposed to certain financial risk such as market risk (Including currency risk and other price risks), credit risk and liquidity risk that could have significant influence on the company's business and operational/financial performance. The Board of directors reviews and approves risk management framework and policies for managing these risks and monitor suitable mitigating actions taken by the management to minimize potential adverse effects and achieve greater predictability to earnings.

44. Credit Risk

Credit risk refers to the risk that counterparty will default on its contractual obligations resulting in financial loss to the company. The company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, a means of mitigating the risk of financial loss from defaults.

The company makes an allowance for doubtful debts/advances using expected credit loss model.

ARUNJYOTI BIO VENTURES LIMITED

45. Liquidity risk

Liquidity risk refers to the risk that the company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as pre requirements. The Company's exposure to liquidity risk is minimal as the promoters of the company is infusing the funds based on the requirements.

46. Amounts have been rounded off to nearest Rupee.

As per our Report of even date
For M M REDDY & CO.,
Chartered Accountants
Firm Reg No:010371S

For and on behalf of the Board of Directors
Arunjyoti Bio Ventures Limited

CA. M. Madhusudhana Reddy
Partner
Membership No: 213077
UDIN: 20213077AAAAHM4139

Sd/-
Pabbathi Praveen Kumar
Wholetime Director cum CFO
DIN:02009879

Sd/-
Babulal Raja Kumar
Wholetime Director
DIN:07529064

Place: Hyderabad
Date : 28/07/2020

If undelivered please return to :

ARUNJYOTI BIO VENTURES LIMITED

(FORMERLY KNOWN CENTURY 21st PORTFOLIO LIMITED)

Plot No. 45, P & T Colony,

Karkhana, Secunderabad – 500009

E-mail id: cenport@gmail.com